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Abstract 
Traumatic brain injury (TBI) is a leading cause of disability worldwide. Annually, 
150 to 200/1,000,000 people become disabled as a result of brain trauma. Axonal 
degeneration is a critical, early event following TBI of all severities but whether axon 
degeneration is a driver of TBI remains unclear. Molecular pathways underlying the 
pathology of TBI have not been defined and there is no efficacious treatment for TBI.  
Despite this significant societal impact, surprisingly little is known about the 
molecular mechanisms that actively drive axon degeneration in any context and 
particularly following TBI. Although severe brain injury may cause immediate disruption 
of axons (primary axotomy), it is now recognized that the most frequent form of 
traumatic axonal injury (TAI) is mediated by a cascade of events that ultimately result in 
secondary axonal disconnection (secondary axotomy) within hours to days.  
Proposed mechanisms include immediate post-traumatic cytoskeletal 
destabilization as a direct result of mechanical breakage of microtubules, as well as 
catastrophic local calcium dysregulation resulting in microtubule depolymerization, 
impaired axonal transport, unmitigated accumulation of cargoes, local axonal swelling, 
and finally disconnection. The portion of the axon that is distal to the axotomy site 
remains initially morphologically intact. However, it undergoes sudden rapid 
fragmentation along its full distal length ~72 h after the original axotomy, a process 
termed Wallerian degeneration.  
Remarkably, mice mutant for the Wallerian degeneration slow (Wlds) protein 
exhibit ~tenfold (for 2–3 weeks) suppressed Wallerian degeneration. Yet, 
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pharmacological replication of the Wlds mechanism has proven difficult. Further, no one 
has studied whether Wlds protects from TAI. Lastly, owing to Wlds presumed gain-of-
function and its absence in wild-type animals, direct evidence in support of a putative 
endogenous axon death signaling pathway is lacking, which is critical to identify original 
treatment targets and the development of viable therapeutic approaches.  
Novel insight into the pathophysiology of Wallerian degeneration was gained by 
the discovery that mutant Drosophila flies lacking dSarm (sterile α/Armadillo/Toll-
Interleukin receptor homology domain protein) cell-autonomously recapitulated the Wlds 
phenotype. The pro-degenerative function of the dSarm gene (and its mouse homolog 
Sarm1) is widespread in mammals as shown by in vitro protection of superior cervical 
ganglion, dorsal root ganglion, and cortical neuron axons, as well as remarkable in-vivo 
long-term survival (>2 weeks) of transected sciatic mouse Sarm1 null axons. Although 
the molecular mechanism of function remains to be clarified, its discovery provides 
direct evidence that Sarm1 is the first endogenous gene required for Wallerian 
degeneration, driving a highly conserved genetic axon death program. 
The central goals of this thesis were to determine (1) whether post-traumatic 
axonal integrity is preserved in mice lacking Sarm1, and (2) whether loss of Sarm1 is 
associated with improved functional outcome after TBI. I show that mice lacking the 
mouse Toll receptor adaptor Sarm1 gene demonstrate multiple improved TBI-
associated phenotypes after injury in a closed-head mild TBI model. Sarm1-/- mice 
developed fewer beta amyloid precursor protein (βAPP) aggregates in axons of the 
corpus callosum after TBI as compared to Sarm1+/+ mice. Furthermore, mice lacking 
Sarm1 had reduced plasma concentrations of the phosphorylated axonal neurofilament 
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subunit H, indicating that axonal integrity is maintained after TBI. Strikingly, whereas 
wild type mice exhibited a number of behavioral deficits after TBI, I observed a strong, 
early preservation of neurological function in Sarm1-/- animals. Finally, using in vivo 
proton magnetic resonance spectroscopy, I found tissue signatures consistent with 
substantially preserved neuronal energy metabolism in Sarm1-/- mice compared to 
controls immediately following TBI. My results indicate that the Sarm1-mediated 
prodegenerative pathway promotes pathogenesis in TBI and suggest that anti-Sarm1 
therapeutics are a viable approach for preserving neurological function after TBI.  
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CHAPTER I: 
INTRODUCTION 
Epidemiology of traumatic brain injury 
Traumatic brain injury (TBI) represents a major public health problem affecting 
more than 10 million people worldwide each year.1 It is the leading cause of long-term 
disability among children and young adults in high-income countries and results in a 
high burden on patients’ families and friends.2 Annually, 150 to 200/1,000,000 people 
become disabled as a result of brain trauma.3 According to projections from the World 
Health Organization a significant rise in TBI incidence is expected by 2020, which is 
related to a sharp increase in traffic accidents in low- and middle income countries.4,5 
Although TBI-related disability disproportionally affects young individuals due to their 
greater life expectancy, it is a disease of all ages with a trimodal incidence distribution 
across age groups.6 The highest risk is among children aged 0-4 years (1,218 per 
100,000) followed by age groups 15-19 years (896 per 100,000), and ≥75 years (932 
per 100,000).6 Across all ages there is male preponderance of TBI incidence with males 
approximately 1.4 times more likely to sustain a TBI than females.6 
In the USA, each year approximately 1.7 million people present to emergency 
rooms after suffering a TBI.6 Of these more than 300,000 patients require hospital 
admission, 52,000 of whom ultimately die as a consequence of their TBI and related 
injuries.6 It has been estimated that an additional 1.1 million TBI patients seek medical 
attention in community health clinics and are seen by office based physicians.7 
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Accordingly, almost 3 million TBI patients require medical attention in the USA per year. 
Although the precise proportion of TBI survivors living with TBI-related disability is 
unknown, it has been estimated that about 5.3 million people live with long-term or life-
long disability after hospitalization for TBI in the USA alone, corresponding to about 1 in 
60 people.8,9 Epidemiological data on TBI indicate an annual cumulative incidence of 
hospitalized and fatal TBI of approximately 41-600 per 100,000 population with 
substantial variation between different geographic localities and countries.2,6,7,9-11 The 
estimated overall economic burden in the USA is a staggering US$ 60 – 406 billion, 
whereby the majority of the cost relates to work loss and loss of quality of life.7,12  
Nevertheless, these estimates do not include the large number of patients who 
do not seek medical attention after mild TBI, such as after concussions related to 
recreational activities, household accidents, and after military deployment, which led to 
the coining of the term ‘silent epidemic’.10 Approximately 70-90% of all TBIs are 
considered mild;2 yet, despite the seemingly mild injury severity a significant subset of 
these patients suffer residual deficits including cognitive, behavioral, and emotional 
consequences that adversely affect a person’s ability to perform daily activities and to 
return to work.13-17 For this reason mild TBI has been declared a major public health 
problem by the National Institutes of Health in 1999.18 Given the high clinical relevance 
of mild TBI this thesis specifically sought to determine the molecular mechanisms of 
acute brain trauma using a mild TBI animal model.  
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Definition and classification of traumatic brain injury 
TBI is a highly heterogeneous condition resulting from a variety of injury types 
and severities. Traditionally, TBI has been classified according to the injury mechanism 
(closed head, blast, penetrating, crash), clinical severity (e.g., level of consciousness as 
assessed by the Glasgow coma scale [GCS]19 or presence of additional non-brain 
injuries as assessed by the Injury Severity Score20), structural damage as determined 
by neuroimaging (e.g., Marshall computed tomography [CT] classification21 or the 
Rotterdam CT Score22), and prognosis.23,24  
Closed head injury constitutes the most common TBI mechanism with the leading 
causes relating to falls and traffic-related injuries.6 Although penetrating TBI, such as 
after gunshot wounds and battle field injuries, represents only a small fraction of all TBI 
it is often devastating and associated with a high mortality rate of 44-100%.25,26 In 
recent years, there has been a significant rise in the incidence of blast-related TBI 
related to changes in modern warfare that has seen an increased use of improvised 
explosive devices. Although overall mortality has decreased on the battle field through 
improved protective armor and battle field medical care, it is increasingly recognized 
that standard body armor does not provide the same protection from blast injuries as 
from ballistic injury.27 Long underrecognized, given absent overt tissue damage on 
standard neuroimaging, it is now appreciated that blast injuries frequently cause unique 
microscopic brain damage that associates with lasting neurocognitive symptoms.27  
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Irrespective of the injury mechanism it is critical to accurately determine the 
clinical severity. Probably the most commonly used clinical TBI classification system is 
the GCS, which has evolved into a universal classification tool for the severity of TBI 
since its inception more than 4 decades ago.5,19,28 The GCS assigns a sum score that 
ranges from 3 (worst) to 15 (best) of the best eye, motor, and verbal response scales.19 
Based on the sum score, TBI severity is graded as mild (14-15), moderate (9-13), and 
severe (3-8), whereby the GCS cut off for mild TBI is sometimes defined as GCS 13-
15.29 A major advantage of the GCS relates to the fact that it is widely recognized, 
allows for rapid and reliable patient assessment, has been proven and repeatedly 
validated for use in various clinical settings, and has additional use for outcome 
prediction.30 Nevertheless, it is frequently limited for the assessment of the most 
severely affected patients given potential confounding of the mental status by medical 
sedation, paralysis, intoxication, and need for intubation (and thus inability of the patient 
to provide verbal responses), in the setting of facial injuries (inability to assess eyes) as 
well as due to its varied inter-rater variability particularly among inexperienced raters.30 
Furthermore, it overproportionally weighs the motor subscale while at the same time not 
capturing focal deficits:30 a hemiplegic patient may score fully on the motor GCS as long 
as he has full use of the unaffected side. Although novel rating scales have been 
introduced for the assessment of the moderate-to-severe TBI none has gained similar 
universal acceptance as the GCS to date.26,30,31 Lastly, available severity scores are 
heavily biased towards recognizing severe deficits. Although the overwhelming majority 
of all TBIs in both civilian and military populations are mild in nature, available clinical 
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severity scales lack the ability to differentiate mild injuries and accurately predict long-
term sequelae following mild TBI.6,32,33 
Assessment of structural brain injury by neuroimaging has the advantage that it is 
not influenced by clinical confounders of clinical severity rating tools. Given its 
widespread availability, rapid image acquisition, and absent contraindications, head CT 
remains the standard diagnostic modality to assess TBI-related hemorrhagic and non-
hemorrhagic injuries.34 The Marshall-CT classification is probably the most frequently 
used CT classification scheme for the assessment of structural TBI.21 It considers the 
degree of brain swelling, mass lesions, and surgical evacuation to classify brain 
damage into 6 categories.21 However, the CT-based classification is limited due to the 
broad differentiation between diffuse injuries and mass lesions and is particularly poor 
at identifying traumatic axonal injury (so-called “stealth” pathology), which particularly 
limits its use in mild TBI.35,36 To overcome the limitations of CT for the assessment of 
subtle, but clinically important brain injury, various experimental brain magnetic 
resonance imaging (MRI) techniques have been developed that are highly promising for 
the detailed evaluation of axonal injury and to improve on outcome predicition such as 
diffusion tensor imaging (DTI) MRI.37,38 However, though conventional MRI adds 
prognostic value with superior discrimination39 compared to CT,21,22 it is much less 
feasible in the early acute phases of trauma related to patient instability for transport 
and lying flat during the relatively long acquisition time.39,40 Thus, until MRI, including 
advanced and highly sensitive techniques such as DTI, becomes a widespread 
standard modality for acute brain assessment in TBI, CT remains the mainstay of 
imaging evaluation during the critical acute phases of trauma.  
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In this dissertation, I probe brain integrity after mild TBI through a combination of 
behavioral, neuroimaging, cerebral blood flow, and histological assessments to account 
for the fact that outcome prognostication for this form of TBI remains challenging due to 
its heterogeneous presentation and pathophysiology that escapes detailed assessment 
by standard clinical tools that requires the integrative, simultaneous evaluation of 
multiple injury-related assessment domains.  
  
7 
Pathophysiology of brain trauma 
Mechanical loading through sudden impact, acceleration, rotation, or explosive 
blast generate both localized and distributed forces throughout the brain. Often 
occurring in combination, these mechanical forces are associated with different injury 
types to the brain. Localized forces such as through a blunt hit against the head typically 
contribute to brain injury through deformation of the brain tissue during impact against 
the rigid skull and cause focal injuries such as brain contusion and hemorrhage near the 
impact site.41-43 Focal injuries tend to increase with greater injury severity as they are 
the consequence of direct impact on the brain that results in tissue compression at the 
site of impact (coup) or the tissue opposite to the impact (contre-coup).44-46  
Conversely, diffuse injuries dominate the neuropathological consequences after 
mild closed head TBI and explosive blast. The most common diffuse injury types are 
diffuse vascular and axonal injury that result from blast-induced increased pressure 
gradients; as well as rapid acceleration, deceleration, and rotation that are associated 
with diffuse brain tissue deformation and injury due to inertial effects whereby rotational 
brain acceleration more readily induces injury than isolated linear acceleration.42,47-49  
As previously discussed, clinically available brain imaging with CT and MRI can 
readily identify focal brain pathology but has a low sensitivity for detecting diffuse brain 
injury, which may explain why the extent of detected brain pathology often does not well 
correlate with clinical outcomes, particularly after milder TBI.50 Indeed, it is now well 
understood that diffuse brain injury is associated with widespread disruption of 
neuronal, axonal, and vascular integrity.51-56 Injury to the neurovascular compartment 
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and the interaction between neurons and the vasculature (so called neurovascular unit) 
leads to disordered regulation of cerebral perfusion, metabolism, and brain function.   
 
Traumatic vascular injury, brain hypoperfusion, and cerebral metabolic 
dysfunction 
Like no other organ the brain relies on a steady state of blood supply for the 
delivery of oxygen and nutrients (glucose) to meet its high metabolic demands. The 
degree of brain perfusion is controlled via three main mechanisms. Cerebral 
autoregulation allows to maintain a constant cerebral blood flow (CBF) across a wide 
range of cerebral perfusion pressures. Furthermore, CBF can be adjusted through 
cerebral vasoreactivity in response to altered carbon dioxide levels. Lastly, 
neurovascular coupling is the increase in CBF in response to increased neuronal 
activity and metabolic demands. While the exact pathophysiology of traumatic cerebral 
hypoperfusion remains to be elucidated, disruption of each of these mechanisms has 
been described after TBI and associated with impaired brain function after both 
experimental and human TBI.56-64  
 
Cerebral autoregulation  
Pressure induced cerebral autoregulation is typically observed within a cerebral 
perfusion pressure range of 50 to 150 mmHg.65,66 Within this range the cerebral 
vasculature maintains the CBF by dilation and constriction in response to an increased 
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and reduced systemic arterial blood pressure, respectively.65,66 The constriction and 
dilatation occurs primarily in the cerebral arteries, arteriolar vessels, and to a lesser 
degree in the capillaries with the overall vascular response lagging about 10 seconds 
from the systemic blood pressure change.67-69 However, these vessels have only a finite 
ability to vasoconstrict and vasodilate. Accordingly, CBF begins to decline once cerebral 
perfusion pressure falls below the lower limit of the autoregulatory range and vice versa. 
TBI of all severities has been shown to impair CBF autoregulation in response to both 
decreasing and increasing perfusion pressures across all age groups.64,70-75 In its 
extreme, when autoregulatory mechanisms are abolished, the CBF linearly follows the 
cerebral perfusion pressure (CPP) and rapidly leads to cerebral ischemia with 
decreasing systemic blood pressure. Conversely, when the CPP increases cerebral 
hyperperfusion results and this leads to increased intracranial pressure. It needs to be 
emphasized that the  autoregulatory perfusion pressure ranges discussed above are 
variable and also dependent on comorbid conditions. For example, both the lower and 
upper limits are shifted towards higher levels among individuals with chronic 
hypertension or in the setting of increased intracranial pressure (right shift of the 
curve).76 Accordingly, critical cerebral hypoperfusion may already ensue at higher 
cerebral perfusion pressures particularly among the elderly who frequently have 
hypertension and when TBI is complicated by focal mass lesions. For this reason blood 
pressure monitoring and management needs to be individualized after TBI.77 Although 
autoregulatory dysfunction is common after TBI, as many as 10-50% of patients may 
have preserved autoregulatory function particularly after mild TBI.78 Conversely, 
although cerebral autoregulation gradually recovers and typically normalizes by day 14 
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after TBI,57,66,77,79 it may remain perturbed long-term and has been related to lasting 
functional impairment.80,81 
 
Cerebrovascular reactivity  
Compared to the pressure-induced autoregulatory response, cerebrovascular 
reactivity to PaCO2 is typically greater indicating that it has a more direct impact on 
cerebral vessels to dilate and constrict as compared to the CPP.76,77 The physiological 
range of PaCO2 is 35–45 mmHg and with each increase in PaCO2 by 1 mmHg up to 5% 
increase in CBF has been found.79 An acute decrease in PaCO2 to approximately 25 
mmHg (e.g., with hyperventilation) results in cerebral vasoconstriction and a decrease 
of CBF by 30-35%. Conversely, hypercapnia due to hypoventilation or CO2-inhalation to 
a PaCO2 of over 50 mmHg causes cerebrovascular dilatation and increase in CBF by 
about 75%.76 However, the cerebrovascular response to PaCO2 attenuates over several 
hours and baseline CBF levels are reached within about 6 hours despite constantly 
altered PaCO2.76 Because changes in the PaCO2 can profoundly affect cerebral 
perfusion, tight monitoring and maintenance within the physiological range after TBI is 
required in patients to mitigate the risk for hypoperfusion-associated brain injury with 
hypocapnia (PaCO2 <35 mmHg). Conversely, hypercapnia (PaCO2 >45 mmHg) needs 
to be avoided to mitigate the risk for vasodilation-associated cerebral blood volume 
increases, which can raise the intracranial pressure (ICP) and cause secondary brain 
damage. Although cerebral autoregulation and cerebrovascular reactivity are both 
impaired after TBI, the extent of impairment may not correlate and depend on the 
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severity of brain trauma.74,77,82 In particular, completely abolished cerebrovascular 
reactivity has been shown to carry a poor prognosis indicating that cerebrovascular 
reactivity may serve as a more robust predictor of outcome and aid therapeutic decision 
making to maintain CBF and perfusion.74,77,83  
 
Neurovascular uncoupling  
The phenomenon that links transient neuronal (but also glial) activity to a 
corresponding increase in CBF has been termed neurovascular coupling. It is now 
understood that the functional hyperemia accompanying neuronal activity is the result of 
a complex interplay between multiple vasoactive molecules (including ions, metabolic 
by-products, vasoactive neurotransmitters, and vasoactive factors) that are released in 
response to neurotransmitters from neurons and glia to act in concert on endothelial 
cells, pericytes, and smooth muscle cells to result in a highly coordinated adjustment of 
the CBF.84 Correspondingly, perturbations of individual aspects of the complex 
molecular interplay underlying neurovascular coupling have the potential to adversely 
affect the finely tuned blood flow response to neuronal demand. Several studies have 
suggested that during trauma-related cerebral hypoperfusion metabolic needs of brain 
tissue are initially met, but that later neurovascular coupling is lost as evidenced by 
hyperemia beyond physiological values several hours after TBI.62,85-89 The clinical 
importance of neurovascular uncoupling has been highlighted by observations that 
uncoupling by pharmacological means (i.e., in the absence of brain injury and other 
circulatory and neuronal changes) induces cognitive deficits in mice.90 Discussed 
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underlying mechanisms include mitochondrial dysfunction, impaired local oxygen 
diffusion into cerebral tissues, vascular microthrombosis, endothelial cell damage, as 
well as capillary compression due to astrocytic endfeet swelling that leads to functional 
shunting of oxygenated blood through the capillary bed without efficient extraction of 
oxygen.58,61,91  
 
Cortical spreading depolarizations  
A unique cause for profound neurovascular uncoupling after TBI relates to the 
phenomenon of cortical spreading depolarization (CSD). CSDs represent a pathological 
event that has been consistently described in the cerebral grey matter of animals and 
patients with TBI and other brain injuries. CSDs were originally discovered and 
described as spreading depression by Aristides A. P. Leão during his thesis research on 
seizures.92,93 The CSD phenomenon is highly conserved across species, has been 
observed in both invertebrates and vertebrates, and can occur in the cortex, striatum, 
thalamus, cerebellum, brain stem, spinal cord, and retina.94 Although spreading 
depression can be induced in the healthy brain via electrical, chemical, and mechanical 
stimulation, it has been proposed that the occurrence of a spreading depression in the 
perturbed (e.g., ischemic) brain should be more aptly termed CSD because of differing 
pathophysiological details such as a prolonged time course, the possibility to occur in 
compromised brain tissue that is already electrically silent, and, probably most 
important, its contribution to brain injury.95 
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In the unperturbed brain CSDs are associated with normal neurovascular 
coupling to neuronal activation albeit with pronounced alterations of electrical, ionic, and 
metabolic disturbances that can be magnitudes larger than those seen with normal 
electrophysiological activity in the brain.94-96 Interestingly, although the 
electrophysiological features of CSDs are conserved across species and nervous 
tissues, the associated vascular response differs quite substantially depending on the 
experimental condition, species, and the vascular bed.94 Restoration of the ionic 
gradients after a CSD is in part energy dependent and requires a significant rise in O2 
and glucose consumption that is associated with substantial CBF changes that reflect 
multiple opposing vasomotor influences at different stages of the CSD wave.94 The 
prototypical CBF response in the unperturbed brain consists of four components. 
Following initial hypoperfusion (component I) a massive peak hyperemia (component II) 
with 30–250% CBF increase is observed 15-20 s after CSD onset and peaks usually at 
1-2 min.94 Following the initial hyperemia peak a second smaller hyperemia peak 
(component III) with a 10-50% CBF increase is inconsistently observed 3-5 min later 
that can last 4-8 min.94 Finally, prolonged oligemia (component IV) with a CBF reduction 
by 10-40% below baseline may persist for an hour or longer after a CSD.94 Figure 1.1 
depicts the characteristic CBF response to a CSD on the example of the mouse.  
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Figure 1.1 Prototypical CBF response after a cortical spreading depolarization (SD). Original laser speckle 
flowmetry tracing showing the multiphasic cerebral blood flow (CBF) response to a CSD in the cortex of an isoflurane-
anesthetized mouse to demonstrate the timing and magnitude of the four prototypical vasomotor components (I–IV) 
shaping the CBF-response as described in text. From94 (used with permission).  
 
Because restoration of the massive ionic gradients after a CSD requires energy, 
CSDs may have deleterious consequences on tissue viability in the injured brain 
because they aggravate the already tenuous metabolic supply and demand mismatch in 
the affected tissue.97-99 Indeed, among severe TBI up to 56% of patients have been 
shown to have CSDs that are frequently repetitive over hours to days and relate to a 
poor outcome.100-103 However, although it is well established that CSDs occur in the 
setting of catastrophic TBI, their presence and possible contribution to outcome in mild 
TBI remains uncertain.104,105  
In summary, TBI is associated with acute, complex, and heterogeneous CBF 
dysregulation that can lead to profound and long-lasting cerebral hypoperfusion and 
neurovascular uncoupling, which compounds the adverse effects on brain health and 
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overall functional outcome after TBI. For this reason it is critical to characterize the CBF 
dynamics after experimental TBI, which I incorporate in this thesis study.  
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Traumatic axonal injury represents a pathological hallmark of TBI 
Historical perspective of traumatic axonal injury 
The most common diffuse injury type, aside from the previously discussed diffuse 
vascular injury, is diffuse axonal injury (DAI). Originally thought to represent a 
consequence of traumatic vascular injury-related cerebral hypoxia, ischemia, and brain 
herniation as well as other non-mechanical factors,48 it is now recognized that DAI, 
though associated with vascular injury, occurs independently and as a direct 
consequence of TBI and constitutes a critical determinant of post-traumatic functional 
impairment.48,106-110 Specifically, broad injury to axons within the cerebral white matter is 
observed following TBI of all severities.107,111,112 
The term DAI was originally coined to describe the widespread and interspersed 
axonal injury pattern in clinical TBI. In an attempt to more clearly indicate the traumatic 
nature of TBI-related axonal injury and because axonal injury after TAI is not exactly 
diffuse, but rather preferentially involves specific locations within white matter tracts (in 
particular the corpus callosum, cerebral hemispheres, and brainstem) the term 
traumatic axonal injury (TAI) was subsequently introduced.35 Because the distinction 
between DAI and TAI is largely based on historical reasons and TAI is the preferred 
terminology in reference to axonal injury after experimental TBI (the topic of this work), 
TAI will be the terminology used in this text.  
Widespread white matter injury as a unique consequence of chronic TBI was first 
described by Rosenblath in 1899.113 Subsequently, it was recognized that the subtle 
and widespread traumatic white matter injury represents a unique and important 
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consequence of chronic TBI.114-116 From these early studies onward it became 
increasingly clear that axonal pathology was an early event after TBI that could be 
identified across a range of injury severities.117-119 In the early 1980s the now accepted 
concept of TAI was introduced based on extensive neuropathological characterization of 
large series of human TBI as well as based on a landmark non-human primate TBI 
study that established the links between TBI-mechanism, TAI, and functional 
impairment.48,54,108,120  
 
Microscopic findings of TAI 
TAI has been assessed using various standard histological techniques including 
silver staining and hematoxylin & eosin staining techniques to detect axonal swellings or 
bulbs.48,108,114-116 However, immunohistochemical methods using antibodies raised 
against proteins that are concentrated in injured axons, specifically beta amyloid 
precursor protein (βAPP), have the distinct advantage to identify even subtle TAI both 
clinically as well as in experimental studies with high sensitivity within minutes after 
TBI.111,121-127 Although βAPP staining has some caveats including its non-specificity to 
TAI, loss of labeling after about 1 week, as well as the availability of various alternative 
immunohistochemical staining techniques, βAPP-staining remains the gold standard 
technique for the detection of TAI.128-135 For this reason βAPP-immunohistology staining 
was chosen for this study to determine the extent of post-TBI TAI. With this approach it 
is possible to detect axonal swellings, which refer to a localized axonal distension 
(“axonal varicosity”) that commonly occurs in a periodic (“beaded”) arrangement along 
the length of an otherwise intact axon, whereas axonal bulb (“retraction ball”) refers to a 
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swollen end either proximal or distal to the site of disconnection.35,136 Although axonal 
distension is probably the easiest and most characteristic pathological feature of TAI 
other pathologies including an undulating appearance have been described.137 These 
morphological patterns likely indicate different stages of axon injury progression rather 
than distinct pathological entities.133,137 Therefore, in this study the presence of any of 
these histopathological patterns is considered a sign of axonal injury that leads to 
axonal degeneration.  
 
Mechanism of TAI 
In contrast to many other neurological conditions associated with axonal 
degeneration, TAI has a comparably rapid onset within just a few hours of insult.127,138 
Although severe brain injury may rarely cause immediate disruption of axons (primary 
axotomy), it is now recognized that the most frequent form of TAI is mediated by a 
cascade of events that ultimately results in secondary axonal disconnection (secondary 
axotomy) within hours to days.111,124,139  
The proposed key pathological mechanism underlying secondary axotomy 
relates to trauma induced cytoskeletal disruption. Axons are thought to be particularly 
vulnerable to mechanical forces due to their parallel arrangement within long white 
matter tracts and their ultrastructural linear organization of microtubules and 
neurofilaments.111 Ultrastructural axon cytoskeletal assessment in vitro demonstrated 
periodic breaks of individual microtubules along axons within 2 minutes of axonal 
stretch injury that corresponded regionally with undulations.137,140,141 Following this initial 
phase, axons resume their straight orientation while developing periodically organized 
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axon swellings over an hour that spatially correspond to the undulations; until they 
finally disconnect distal to these swellings (i.e., distal to the microtubular breakage site) 
due to the ensuing transport block for cargoes that causes an unmitigated local cargo 
accumulation and finally secondary axotomy by axonal membrane rupture.137,140-142 
Support for this hypothesis stems from the observation that application of the 
microtubule-stabilizing drug paclitaxel mitigates axonal degeneration after stretch 
injury.140 This proposed sequence of events is summarized in Figure 1.2.  
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Figure 1.2 Proposed mechanism of varicosity formation after traumatic axonal injury. (a) Illustration displaying 
two illustrated microtubules within an intact axon (pre-injury). (b) Following injury, mechanical breaking occurs at 
different sites in microtubules resulting in their misalignment and deformation of the axon observed as two discrete 
undulations. (c) Shortly afterward, catastrophic depolymerization from the broken ends of the microtubules allows the 
undulations to collapse and the axon recovers its linear morphology. (d) Microtubule breakage leads to impaired 
axonal transport, subsequent accumulation of transported cargoes near the microtubule breaking point, likely 
accounting  for the formation of swellings that give axons a varicose appearance following traumatic axonal injury. 
From137 (used with permission).  
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In addition to microtubule disruption, alterations of neurofilaments, which 
represent a major component of the axonal cytoskeleton,143 have also been described 
as an early event after TBI.144 Specifically, reductions in the interfilament spacing due to 
altered phosphorylation or proteolysis of side arms (termed neurofilament compaction) 
has been demonstrated to precede microtubule fracturing.145-147 Both neurofilament 
compaction and microtubule disruption represent early events after TBI indicating that 
cytoskeletal failure is a direct effect of mechanical trauma. While the role of 
microtubules in cytoskeletal disruption has been well characterized, the precise role of 
neurofilament protein pathology in TAI remains to be clarified. For example, it has been 
shown that microtubular breakage and neurofilament compaction do not exactly co-
localize within traumatized axons indicating that they represent different aspects of 
TAI.137,139-141,148,149 Importantly, serologic detection of microtubule and neurofilament 
breakdown products has been shown to correlate with the severity of TBI and it is 
increasingly explored as a non-invasive marker for trauma-related brain injury.150-154 
This study takes advantage of this correlation by using a plasma phosphorylated 
neurofilament heavy chain (pNFH) assay as a complementary method to serially 
determine the extent of TAI after mouse TBI. 
Although cytoskeletal disruption in response to shearing and torsional 
mechanical forces is well documented, the precise mechanism by which TBI initiates 
this process, as well as subsequent secondary axon degeneration, is only incompletely 
understood. It is thought that local intra-axonal calcium dysregulation plays a central 
role in post TBI axonal degeneration. This hypothesis is supported by observations of 
altered calcium ATPase activity and calcium entry into axons after stretch injury.155-158 
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The post-traumatic increase in intra-axonal calcium appears to originate from 
intracellular stores as well as the trans-axolemmal sodium entry via mechanosensitive 
sodium channels that results in the reversal of the Na+/Ca2+ exchanger and opening of 
voltage-gated calcium channels.159,160 The primary mechanism by which Ca2+ is thought 
to lead to cytoskeletal breakdown is via Ca2+-dependent activation of calpain. This 
serine-threonine protease is capable of cleaving critical components of the axonal 
cytoskeleton including neurofilaments and microtubule-associated components such as 
tubulin and spectrin.135,161-167 In addition calpain appears responsible for ion channel 
degradation, which contributes to progressive increases of intra-axonal calcium 
concentrations.159,168 Conversely, inhibition of calpain was found to mitigate TAI as well 
as improve post-traumatic outcome.164,166,169 Figure 1.3 summarizes the major pathways 
that lead to cerebral compromise and functional impairment. 
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Figure 1.3 Summary flow chart of the major molecular pathophysiological pathways of mild TBI. NMDA 
indicates N-methyl-D-aspartate. Used with permission from.46  
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Sarm1-mediated Wallerian degeneration after axon injury 
Intriguingly, the portion of the axon that is distal to the axotomy site remains 
initially morphologically intact. However, it undergoes sudden rapid fragmentation along 
its full distal length after a predictable lag-period of approximately 36-72 hours after the 
original axotomy.106,111,170-174 This process has been termed Wallerian degeneration, 
honoring the British neurophysiologist Augustus Volney Waller who first described 
delayed distal axon degeneration in nerve transection experiments in 1850.173 
Originally, this process was thought to represent the passive wasting away of the distal 
axon portion because of its deprivation from a constant supply of nutrients and other 
molecules from the neuronal cell body. However, this view was fundamentally 
challenged by the serendipitous discovery of a mouse strain expressing the unique 
Wallerian degeneration slow (Wlds) protein, in which the axon distal to the transection 
site remains morphologically and functionally intact tenfold (for 2–3 weeks) longer than 
normal.170,175-177 This remarkable observation raised the possibility that injury-induced 
axonal degeneration must be controlled by a regulated endogenous and genetically 
encoded self-destruction pathway.  
However, pharmacological replication of the Wlds mechanism has proven 
difficult.170 Further, although improved functional outcome after TBI has been described 
in Wlds mice178 no one has studied whether Wlds protects from TAI.179 Lastly, owing to 
Wlds presumed gain-of-function and its absence in wild-type animals, direct evidence in 
support of a putative endogenous axon death signaling pathway has been lacking,170 
which is critical to identify original treatment targets and the development of viable 
therapeutic approaches.  
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Novel insight into the pathophysiology of Wallerian degeneration was gained by 
the discovery that mutant Drosophila lacking dSarm (sterile α / Armadillo/Toll-Interleukin 
receptor homology domain protein) cell-autonomously recapitulated the Wlds 
phenotype.180 Furthermore, artificial activation of SARM1 in intact axons induced 
degeneration181 indicating that SARM1 is both essential and sufficient for axonal 
degeneration. The dSarm gene (and its mouse homolog Sarm1) encodes a protein with 
an Armadillo/HEAT (ARM) domain, two sterile alpha motifs (SAM), and a 
Toll/interleukin-1 receptor homology (TIR) domain. Its necessity for degeneration is 
conserved in mammals as shown by in-vitro protection of superior cervical ganglion, 
dorsal root ganglion, and cortical neuron axons as well as remarkable in-vivo long-term 
survival (>2 weeks) of transected sciatic mouse Sarm1 null axons.180 Sarm1 is highly 
conserved across phyla.182 Sarm1 is enriched in the mouse brain and mutant mice 
lacking Sarm1 display a broadly normal neural development, though a reduction in the 
complexity of neuronal dendritic arborization has been noted.183-185 The discovery that 
axons lacking Sarm1 are protected from injury-induced degeneration provided direct 
evidence that Sarm1 is the first defined endogenous gene required for Wallerian 
degeneration, driving a highly conserved genetic axon death program.180  
Although it has yet to be confirmed that the SARM1-mediated Wallerian 
degeneration pathway plays a critical role in trauma-induced axonal injury and 
degeneration, the data available indicate that the pro-degenerative SARM1 pathway is 
highly conserved and plays an integral role across different axon injury paradigms and 
neurological disorders that involve axon loss. Recent studies have shown that genetic 
depletion of Sarm1 prevents chemotherapy-induced peripheral axon degeneration186 as 
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well as excitotoxicity-induced degeneration of retinal ganglion cells and their axons.187 
Accordingly, it appears possible that blocking Sarm1 could attenuate TAI. Since TAI 
represents the pathological hallmark underlying TBI-induced functional impairment, it 
seems quite possible that mice lacking SARM1 not only exhibit reduced axonal 
degeneration but also improved functional outcomes, which forms the central 
hypothesis of my thesis. 
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The mouse as a model organism to study traumatic brain injury 
Commonly used mouse models of human TBI 
Given the heterogeneous nature and high complexity of TBI-related pathology 
and pathophysiology, no single animal model is capable of mimicking all aspects of 
human TBI. Accordingly, numerous models have been developed, each possessing 
distinct advantages and disadvantages.188-190 Although animal species with larger, 
gyrencephalic brains may exhibit pathophysiology that more closely resembles that of 
humans, high cost and ethical considerations restrict their widespread use. In contrast, 
rodents are particularly advantageous for use in TBI owing to their modest cost, small 
size, availability of standardized functional outcome measurements, and—specifically 
with respect to the mouse—availability of many gene mutants and relative ease of 
genetic manipulation.183,191  
A particular challenge is the modeling of TBI with TAI, because the rotational 
acceleration-deceleration forces required to induce axonal damage increase 
exponentially with decreasing brain sizes; for this reason no single model has been 
developed that reliably produces this type of injury in rodents without causing additional 
massive brain hemorrhage and high mortality.190,192,193 Among the most commonly used 
mouse TBI models designed for the study of the complex molecular cascades 
accompanying TAI188 are the fluid-percussion injury (FPI),194 controlled cortical impact 
injury (CCI),195-198 blast injury,199-201 and weight-drop injury models.191,202-208  
Although the FPI and CCI models have been extensively characterized, are 
highly reproducible, and show a close correlation between injury severity and outcome, 
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they have the main disadvantage that they require a skull trephination to allow for 
rapidly striking the exposed dura mater with either a fluid bolus (FPI) or an impactor 
(CCI).191,194-198 Blast injury is typically induced by exposing the mouse to an 
overpressure gas shock wave of defined size, duration, and intensity delivered within a 
shock tube and has been shown to produce pathology that mimics war-fare related 
injuries as well as chronic, repetitive brain trauma.199-201 However, none of these models 
represents the most common human TBI condition: mild TBI due to blunt, closed head 
trauma. Therefore, using a model that employs a mechanical impact to the closed skull 
promises easier translation of results from ‘bench to bedside’. The weight-drop injury 
model fulfills this requirement by using a guided, free-falling weight onto the intact 
skull.191 A further advantage relates to the brevity of the required surgical procedure as 
well as the ability to easily control injury severity through adjustment of the falling weight 
mass, fall height, and head displacement after impact to produce a reproducible focal 
brain injury that mimics a wide range of mild human closed head injury pathologies 
including TAI.188,191,202-208 In addition, impairment of neurological function that correlates 
with injury severity has been repeatedly demonstrated.191,202,205,206,209,210 Lastly, this 
model can be used to mimic repetitive TBI,211,212 which provides a critical foundation for 
future studies investigating mechanisms of neuroaxonal degeneration in the context of 
repeated TBI, given its purported association with chronic neurodegenerative 
disorders.213-216 To take advantage of these unique properties, a closed head mouse 
mild TBI model is utilized in all trauma studies described in this thesis.  
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Behavioral assessment after closed head TBI in the mouse 
Arguably the most important outcome measure in neurological diseases is 
behavioral function. The Neurological Severity Score (NSS) is a standardized functional 
test battery that has been specifically designed to assess motor and other 
neurobehavioral (dys)function in the closed head mouse TBI model.191,202,209,210 The 
NSS is easy to perform, sensitive to TBI-induced functional deficits, objective in 
interpretation and thus fairly robust against subjective investigator appraisal.191 Equally 
important, it has been shown to correlate highly with the severity of TBI-induced brain 
damage as assessed by histology and brain MRI rendering it suitable for the 
comparison of functional outcomes with the herein used study methods.191 The NSS 
assigns 1 point each for the presence of paresis, failure of the mouse to walk straight, 
failure to exit a circle within 3 minutes, failure to exhibit a startle response to a loud clap, 
absent physiological seeking behavior, inability to cross beams of different width (3, 2, 
and 1 cm, respectively), as well as ability to balance on a 7 mm square and 5 mm round 
stick, respectively (Table 1.1).202,210 Accordingly, a score of zero indicates normal 
function and a score of 10 a maximal deficit. A score of 3-4 at 1-4 hours after TBI is 
considered consistent with a mild injury and a score of >6 considered a severe injury. 
Depending on the injury severity, but also the tested mouse strain, animals 
spontaneously recover until they reach their pre-TBI functional status within 
approximately 1-7 days.191,207,210 Finally, given the number of tests and variability 
between animals and strains, mice may exhibit pre-TBI baseline functional deficits.191 
These potential confounders are considered in this study by serially evaluating animals 
and including a pre-TBI test session.  
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Task  Description Score (success/failure) 
Exit circle Ability and initiative to exit a circle of 30 cm diameter within 3 min 0/1 
Paresis  Paresis of upper and/or lower limb of the contralateral side 0/1 
Straight walk Alertness, initiative and motor ability to walk straight 0/1 
Startle response Innate reflex; the mouse will bounce in response to a loud noise clap 0/1 
Seeking behavior Physiological behavior as a sign of ‘interest’ in the environment 0/1 
3 cm beam Ability to cross a 30-cm long beam of 3 cm width 0/1 
2 cm beam Same task, increased difficulty on a 2-cm wide beam 0/1 
1 cm beam Same task, increased difficulty on a 1-cm wide beam 0/1 
7 mm beam Ability to balance on a beam of 7 mm width for at least 10 s 0/1 
5 mm beam Ability to balance on a round stick of 5 mm diameter for at least 10 s 0/1 
Maximal score  10 
 
Table 1.1 Neurological severity score. Used with permission from.191 
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Significance of the work in this thesis 
In summary, traumatic axonal injury and subsequent Wallerian degeneration of 
the axon represent key pathological events that relate to functional deficits after TBI of 
all severities. Although it is now well established that axon degeneration is an active 
process, the molecular mechanisms driving this process are incompletely understood. 
Discovery of SARM1 as a prodegenerative molecule driving this process has propelled 
the field forward as it provided first evidence for an endogenous axon “suicide” pathway.  
The central goal of this dissertation is to determine whether the Sarm1 pathway 
is critical for trauma-induced axonal degeneration. Specifically, I hypothesize that 
Sarm1 deficiency preserves axonal structure and results in improved functional 
outcome after TBI. To closely mimic the most common form of human TBI I employ a 
mild closed head brain trauma model. 
I first characterize the CBF response to TBI given the reported association 
between traumatic vascular and axonal injury. I provide evidence that mild TBI causes 
profound cerebral hypoperfusion that is consistent with CSD and that relates to worse 
brain tissue integrity and functional outcome. However, I show that Sarm1 wild type and 
knockout mice show a similar CBF-response to TBI assuaging concerns that loss of 
Sarm1 affects traumatic vascular injury, which could have confounded the main 
investigation. I demonstrate that Sarm1 knockout mice have significantly attenuated 
TAI, improved brain metabolism, and functional outcome providing novel insight into the 
pathophysiology of TBI by showing for the first time that TAI after TBI is mediated by a 
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SARM1-associated “programmed axonal death” pathway representing a unique and 
novel target for TAI therapy. 
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CHAPTER II: 
ACUTE CEREBRAL BLOOD FLOW DYNAMICS AFTER 
MOUSE TRAUMATIC BRAIN INJURY 
 
 
 
 
 
 
 
 
 
 
Data in this chapter has been presented at the annual National Neurotrauma Society 
meeting 2016 as: 
 
Bouley J, Henninger N. Association between hyperacute, transient, cerebral blood flow 
changes and outcome after mild closed head injury in the mouse. 
 
Author contributions: J.B. conducted animal surgery, behavioral testing, histological 
preparations, and genotyping. N.H. designed the study, conducted animal surgery, laser 
Doppler measurements, histology analyses, statistical analyses, wrote the abstract, and 
presented the data.   
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Summary 
Traumatic vascular injury and cerebral hypoperfusion accompany TBI and have 
been associated with a worse outcome. However, the acute CBF dynamics after mild 
closed head TBI have not been well characterized and it remains unclear whether 
observed CBF alterations related to a worse outcome. This study shows that mild TBI 
induces a siginficant decrease in the CBF immediately following the traumatic impact, 
which is followed by a progressive decline in CBF to reach a nadir (median 56±5% of 
baseline values) at 20 min. Subsequently, the CBF recovers to approximately 80% of 
baseline by 90 min after TBI. When stratified according to the median CBF at 20 min, 
mice with a CBF below the median showed significantly greater histological tissue injury 
and worse functional outcome as compared to mice with a CBF remaining above the 
median. I show that the CBF responses were unrelated to cardiovascular depression as 
indicated by a stable mean arterial blood pressure throughout the observation period. 
Careful examination of the temporal and spatial CBF responses to TBI revealed cortical 
blood flow dynamics that were prototypical for those seen in the wake of CSDs. These 
results indicate that mild TBI in the used mouse model triggers CSDs in a subset of 
animals, which is associated with profound, transient depression of CBF, as well as 
worse histological and functional integrity after TBI. These observations may inform 
experimental study design and provide novel avenues for outcome prediction and 
therapeutic intervention. 
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Introduction 
Profound and lasting decreases in CBF have been consistently observed after 
moderate-to-severe TBI. However, relatively little is known about the association 
between mild TBI and very early CBF dynamics and how they relate to the degree of 
brain injury and functional outcome. Specifically, there is a paucity of data regarding the 
relation of early CBF-changes on outcome. The importance of TBI induced CBF 
alterations is highlighted by the fact that post traumatic hypoperfusion has been 
associated with adverse functional outcomes because intact neuronal metabolism relies 
on a constant, and carefully adjusted, blood supply, which, when disrupted, impairs 
neuronal function and structural integrity.56-64  
To gain novel insight into the pathophysiological CBF dynamics after TBI this 
study sought to determine (i) the temporal and spatial CBF responses to TBI in the 
immediate post-injury period, as well as their relation to (ii) the mean arterial blood 
pressure and (iii) the degree of histological and functional outcome in an established 
mouse TBI model.  
The results gained from these experiments will lay the foundation for the studies 
designed to examine the central thesis goal: to determine whether blocking the axon 
prodegenerative Sarm1 pathway attenuates TAI after TBI. This is important because it 
is unknown whether Sarm1 wild type and knockout mice have a differential vascular 
response to trauma, which could confound data interpretation.  
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Material and Methods 
Ethical approval 
All procedures were approved by the University of Massachusetts Medical 
School Institutional Animal Care and Use Committee (Protocol #A-2405-15).  
 
Mice 
Spontaneously breathing male C57BL6/J mice (Jackson Laboratories) age 8-12 
weeks were subjected to closed head injury (n=38 [n=32 over the ipsilesional and n=6 
over the contralesional hemisphere]) or sham injury (n=6) to assess CBF-changes after 
TBI. A femoral artery catheter was placed in an additional 6 TBI mice to continuously 
assess the mean arterial blood pressure during the first 60 min after TBI and in 5 mice 
cortical light transmission was used to determine spatial CBF dynamics after TBI. Mice 
who had a femoral catheter placed (n=6) were euthanized immediately after the end of 
the CBF measurements and did not undergo histological assessment.  
 
Anesthesia, analgesia, and TBI induction 
Animals were anesthetized with isoflurane (5% for induction, 2% for surgery, 
1.5% for maintenance) in room air. Anesthesia was discontinued immediately prior to 
TBI and sham injury. Body temperature was monitored continuously with a rectal probe 
and maintained at 37.0 ± 0.5 °C. To alleviate pain,  animals received 0.05 mg/kg 
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subcutaneous buprenorphine (Patterson Veterinary, Devens, MA, USA) 30 min before 
the end of anesthesia and every 6 h afterwards for 24 h. Additionally, each animal 
received 5 mg/kg subcutaneous carprofen (Patterson Veterinary, Devens, MA, USA) at 
the end of the anesthesia.  
Closed head TBI was produced using a weight drop device as previously 
described in detail and as adapted for use in mice191,217 with the following modified 
specifications: Briefly, the skull was exposed, anesthesia discontinued, and the animal 
positioned on a 6.4 mm thick Ethylene Propylene Diene Monomer (EDPM) rubber 
surface (60 durometer hardness) with the head placed under the weight drop device. A 
weight (50 g) was freely dropped 15 cm to strike a cylindrical polyacetal transducer rod 
(Delrin©, tip-diameter 2 mm, 17.4 g) that was placed with its tip directly on the mouse’s 
skull (-2.4±0.3 mm posterior and 2.6±0.3 mm lateral from Bregma) under the tip at an 
angle of 90° (Figure 2.1 A-C). Holding the transduc er rod with one hand immediately 
following the initial impact prevented rebound impact. Following TBI, skulls were 
examined for potential fracture and the wound closed with interrupted sutures. Sham 
animals were anesthetized, surgically prepared and placed under the impact device, but 
were not subjected to injury.  
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Figure 2.1 Traumatic brain injury setup. (A) Schematic of the impact device (adapted from208). (B) Approximate 
impact center over the intact mouse skull. (C) Impact area (orange) relative to the mouse brain (adapted from 218). 
Figure modified from.219  
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CBF measurement 
CBF was measured in animals using a PR407-1 straight needle LDF-probe 
(Perimed, Järfälla, Stockholm, Sweden) connected to a standard laser Doppler monitor 
(PF5010 LDPM Unit and PF5001 main unit, Perimed, Järfälla, Stockholm, Sweden). 
The probe was placed over the traumatized hemisphere (approximately 3 mm posterior, 
6 mm lateral, and 1 mm ventral to the Bregma) on the intact lateral aspect of the skull to 
assess CBF (Figure 2.2 A) 220. A stable baseline was established and recorded for 15 
min, TBI was induced, anesthesia resumed following return of regular spontaneous 
breathing, and relative regional CBF (rrCBF) was continuously assessed for 90 min. For 
analysis, values were averaged across 1 min epochs at the designated time points (at 
baseline as well as 1, 5, 10, 15, and 20 min as well as every 10 min afterwards).  
 
Figure 2.2 Laser Doppler setup. (A) Approximate location of the laser Doppler probe relative to the impact site 
(blue). (B) Representative relative regional cerebral blood flow (rrCBF) time curve over the right, traumatized 
hemisphere as assessed by laser Doppler (arbitrary units). Figure modified from.219   
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Cortical light transmission 
After midline incision and scalp reflection, the intact skull overlying both 
hemispheres was covered with a thin layer of mineral oil to prevent drying and enhance 
transparency. Images were continuously obtained every 2 s from pre-TBI to 30 min 
post-TBI using a 3.1 megapixel microscope digital camera (Model #300MU-CK, 
AmScope, Irvine, CA, USA). Raw images (10x; 2048x1536 resolution) were converted 
off-line to inverted grey-scale (arbitrary units) and by subtracting each image from the 
subsequent image to highlight temporal changes using Matlab (version R2016a, 
MathWorks, Natick, MA, USA).  
 
Neurologic evaluation 
Presence of seizure activity was evaluated clinically (facial twitching as well as 
tail, forelimb, and hindlimb tonic-clonic or tonic movements). All seizures occurred while 
animals were still unconscious. Therefore, no attempt was undertaken to grade seizure 
severity according to previously developed grading scales as these are partially based 
on loss of posture in previously conscious animals.221 
Sternal recumbency was measured as the time (s) from TBI/sham injury to 
righting from a supine to prone position after discontinuation of anesthesia.  
The NSS was assessed prior to TBI as well as at 2 h, 24 h, and 48 h, 7 d, 14 d, 
21 d, and 28 d postoperatively as previously described in detail.191 To account for the 
fact that with repeat testing animals no longer crossed the beams consistently due to 
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inactivity, we modified the readout as follows: If a mouse did not cross the 1, 2, or 3 cm 
beams within the allotted time of 3 min, it was gently nudged once. If the mouse then 
successfully crossed the beam it was assigned a score of zero. Only if they still did not 
cross were they assigned a score of one. In addition, mice were tested on all beams 
irrespective of whether they crossed the next wider beam (e.g., if a mouse did not cross 
the 3 cm beam but then crossed the 2 and 1 cm beams it was assigned a total of 1 point 
for these three subtests).  
 
Histological assessment 
For histology, animals received an overdose of pentobarbital (150 mg/kg Fatal-
Plus, Vortech Pharmaceuticals). Then animals were perfused under isoflurane 
anesthesia through the ascending aorta with 50 mL saline and then with ice cold 
phosphate-buffered 4% paraformaldehyde (PFA) for 10 min. Brains were removed from 
the cranium, postfixed overnight in the same fixative, and then stored in 0.5% PFA at 
4°C until further processing. Prior to paraffin emb edding, brains were pre-sectioned 
using a brain matrix. Histological paraffin sections, 10-µm thick, were obtained from a 
slice below the impact site and evaluated with immunohistochemistry. All histological 
analyses were performed by an investigator blinded to the animal groups (N.H.). 
Immunohistochemistry was performed against βAPP (1:200, CT695, polyclonal rabbit, 
Zymed, San Francisco, CA, USA) as previously described.217 Briefly, for antigen 
retrieval, sections were washed for 5 min with phosphate buffered saline (PBS) and 
three times for 5 min with 1% PBS + Triton. Endogenous peroxidase was blocked with 
0.5% H2O2 in PBS and methanol (1:1) for 30 min and sections heated for 20 min in a 
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600 W-microwave. After incubation in normal swine serum (10%) for 30 min followed by 
the primary antibody overnight at 4°C, immunoreacti vity was visualized by the avidin–
biotin complex method (Vectastain, Vector Laboratory Inc.) with consecutive enhanced 
diaminobenzidine staining. Omitting the primary antisera in a subset of control slides 
resulted in no immunostaining. 
To evaluate axonal injury, the number of βAPP immunopositive axon profiles 
were quantified within the corpus callosum. To this end all axons that included axonal 
deposits, swelling, and bulbs were systematically counted in non-overlapping fields of 
view (FOV) at a magnification of 63x. Counts were conducted in 2 adjacent sections 
(100 µm apart) from beneath the impact center to obtain the mean number of βAPP 
immunopositive axonal profiles across the width of the entire corpus callosum. βAPP 
has been shown to localize almost exclusively to the proximal (but not distal) end of the 
injured axon and identifies axons that proceed towards complete disconnection and 
degeneration.194,222 This property of the βAPP stain has the advantage that it minimizes 
the risk for multiple counting of the same injured axon and thus overestimation of the 
degree of axonal injury.  
To assess cell death, the In Situ Cell Death Detection Kit (Sigma-Aldrich, 
Billerica, MA, USA) was used following the manufacturer’s instructions. Samples were 
imaged at 10x magnification to quantify the number of terminal deoxynucleotidyl 
transferase-dUTP nick end labeling (TUNEL) / 4',6-diamidino-2-phenylindole (DAPI) co-
stained cells in each section and averaged for both sections to provide the final count. 
Cell counts were counted separately for the corpus callosum, caudate putamen, and the 
cerebral cortex.  
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Statistics 
Unless otherwise stated, continuous variables are reported as mean ± SEM and 
categorical variables are reported as proportions. Normality of data was examined using 
Shapiro-Wilk test. Between-group comparisons for continuous variables were made with 
unpaired t-Test, Mann-Whitney U-test, Kruskal Wallis with post-hoc Dunn’s method, 
two-way repeated measures analysis of variance (ANOVA), and two-way ANOVA as 
appropriate. Categorical variables were compared using the χ2-test or Fisher exact test 
as appropriate. Two-sided significance tests were used throughout and a two-sided 
P<0.05 was considered statistically significant. All statistical analyses were performed 
using SigmaPlot 12.5 (Systat Software, Inc., Germany) or IBM® SPSS® Statistics 22 
(IBM®-Armonk, NY).   
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Results 
Cerebral blood flow response to trauma 
Figure 2.3 summarizes the temporal evolution of the rrCBF changes observed in 
sham and TBI animals during the first 90 min after trauma. In sham operated animals 
rrCBF remained stable over the 90 min observation period. In contrast, there was an 
immediate, progressive reduction of the rrCBF in the ipsilateral, traumatized hemisphere 
reaching a nadir of 56±5% of baseline values by 20 min post TBI. Thereafter rrCBF 
gradually recovered to 81±3% of pre-TBI values by 90 min. Over the contralesional, 
non-traumatized hemisphere rrCBF also immediately declined after TBI to 75±6% of 
baseline values by 1 min post TBI, but rapidly recovered to 90±3% of baseline values by 
5 min and remained stable afterwards over the remaining observation period.  
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Figure 2.3 CBF responses after TBI. Temporal evolution of the relative regional CBF (rrCBF) in the ipsilesional 
(blue circles) and contralesional (grey circles) hemisphere after traumatic brain injury (TBI) or sham (open circles) 
surgery. TBI mice had a significant decrease in the rrCBF immediately following impact with a progressive decline to 
a nadir (median 56±5%) at 20 min and subsequent recovery to 81±3% by 90 min. rrCBF was relatively less affected 
in the non-traumatized hemisphere. There were significant group (P<0.001) and time (P<0.001) effects as well as 
presence of a significant group x time (P<0.001) interaction (*P<0.05 for within-group comparisons versus baseline; 
#P<0.05 for between-group comparisons versus sham; two-way RM ANOVA with post-hoc Holm-Šídák test).  
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Reduced CBF is associated with histological markers of brain injury 
Sham animals (n=6) had virtually no TUNEL positive cells. Overall, in TBI mice 
(n=24) there was a trend towards a greater number of apoptotic cells in the traumatized 
compared to the non-traumatized hemisphere (P=0.1470). This trend was similar for all 
investigated regions and only reached significance for the corpus callosum (P=0.0335) 
but not the caudate putamen (P=0.5538) and cerebral cortex (P=0.2251; Figure 2.4).   
 
Figure 2.4 Comparison of apoptotic cell death in the ipsi- versus contralesional hemisphere. Quantification of 
apoptotic cell profiles within the traumatized versus contralesional, non-traumatized (grey) hemisphere at 48 h after 
TBI (n=24). There were significantly more apoptotic cells in the ipsilesional versus contralesional corpus callosum but 
not the caudate putamen or cerebral cortex. Sham animals (n=6) had virtually no TUNEL positive cells and data are 
omitted from the figure for clarity (Mann-Whitney U-test). Cell counts are averages from 2 adjacent sections (100 µm 
apart) from beneath the impact center.   
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Strikingly, there was substantial variability in the degree of the ipsilesional CBF 
reduction during the first 60 min with the CBF ranging from 24.5% to 104.9% of baseline 
values at 20 min between mice. To determine whether the degree of CBF-reduction 
relates to the extent of histological brain injury and functional outcome, TBI mice with 
available ipsilesional CBF measurements were assigned to “low” versus “high” CBF 
groups based on the median CBF measured over the traumatized hemisphere at the 20 
min nadir (56±5% of baseline). Using this stratification scheme, substantial differences 
in the temporal rrCBF evolution between low and high CBF mice were noted from 1 to 
60 min after TBI (Figure 2.5). However, by 70 min rrCBF was similar between 
subgroups.  
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Figure 2.5. Stratification of TBI-related CBF responses to low versus high. Temporal evolution of the relative 
regional cerebral blood flow (rrCBF) after TBI in mice stratified according to their CBF above (high CBF, yellow 
triangles) or below (low CBF, red triangles) the 20 min CBF nadir. Despite significant early between-group differences 
in the hyperacute rrCBF, values in both groups were similar by 70 min post TBI (***P<0.001; *P<0.05 for between-
group differences). There were significant group and time effects, as well as presence of a significant group x time 
interaction (P<0.001, each). In both groups post-TBI values remained significantly below baseline throughout the 
entire observation period (P<0.05 for each time point). All statistical comparisons were made by RM-ANOVA with 
post-hoc Holm-Šidák test. Due to movement related artifacts CBF was not recorded at the time of impact.   
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Histological comparison indicated significantly greater numbers of TUNEL and 
βAPP positive cell profiles in the traumatized hemisphere in low versus high CBF mice 
(P<0.05 each; Figure 2.6 A-B).   
 
Figure 2.6. Low CBF mice have greater tissue injury. Histological comparison of low (red bars; n=12) with high 
(yellow bars; n=12) CBF mice 48 h after TBI. High CBF mice had significantly fewer (A) TUNEL and (B) βAPP 
positive profiles in the injured hemisphere than high CBF mice indicating that lower CBF relates to a greater degree 
of apoptotic cell death and traumatic axonal injury (Mann-Whitney U test).  
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Lower CBF relates to worse neurological function 
There was no significant difference in the proportion of impact seizures 
immediately after trauma in low (52.9%; n=9 of 17) versus high (40%; n=6 of 15) CBF 
mice (P=0.502; Fisher exact test).  
Furthermore, there was no difference in the time to regain sternal recumbency 
after discontinuation of anesthesia at the end of the observation period in low (339±68 
s; n=12) versus high (460±75 s; n=12) CBF mice (P=0.964; t-Test).  
Neurological function was serially assessed by the NSS. I found that compared to 
pre-TBI, mice with a lower CBF remained significantly impaired by 48 h post-TBI, 
whereas mice with a high CBF showed no significant functional deficits by 24 h (Figure 
2.7 A). The differences between the two CBF-groups were mainly attributable to worse 
performance on 7 mm beam balancing, 10 mm beam balancing, startle response, and 
circle exiting in low CBF mice (Figure 2.7 B-D).  
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Figure 2.7 Acute CBF responses impact functional outcome. Neurological severity score (NSS) before and after 
TBI stratified by low versus high CBF. (A) By 24 h after TBI, there was no significant difference in the NSS to pre-TBI 
values in high CBF mice. Conversely, in low CBF mice a significant difference remained by 48 hours (*P<0.05 versus 
baseline; two-way RM ANOVA). (B-D) Differences in the NSS between low and high CBF groups at 24 h and 48 h 
were driven by the subscores derived from the 7 mm beam balancing, 10 mm beam balancing, startle response, and 
circle exiting (blue arrowheads; two-way RM ANOVA: P<0.05 for between group differences; group x time interaction 
P=0.0464). 
  
52 
Acute CBF dynamics are consistent with the phenomenon of traumatic CSD 
Given the transient and heterogeneous nature of the observed profound cerebral 
hypoperfusion after TBI, this followup study sought to determine whether the CBF 
dynamics were related to global cardiovascular depression and systemic hypotension 
as well as to assess whether the temporal and spatial blood flow dynamics in the 
cerebral cortex indicate cortical spreading depolarization. By concurrently assessing the 
mean arterial blood pressure and rrCBF it was noted that there was no significant 
change in the MAP throughout the observation period (Figure 2.8). In contrast, 
characteristic rrCBF changes were observed after TBI that closely match the CBF 
dynamics seen in CSDs indicating the profound CBF alterations occurring in this mouse 
head injury model are driven by CSDs (Figure 2.8).  
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Figure 2.8 Absent association between systemic blood pressure and acute cerebral blood flow. Temporal 
evolution of the mean arterial blood pressure (MAP) and relative regional cerebral blood flow (rrCBF) during the first 
60 min after TBI in 6 mice. There was no significant change in the MAP (red circles) during the study period (one-way 
RM ANOVA, P=0.08). Conversely, rrCBF (blue triangles) significantly declined by 1 min, partially recovered, and then 
demonstrated a secondary decline with significantly depressed rrCBF from approximately 6 -30 min after TBI after 
rrCBF again recovered (*P<0.05 versus baseline; one-way RM ANOVA on Ranks with post hoc Dunnett test). The 
observed rrCBF dynamics match the prototypical four components (I-IV) observed in the wake of a cortical spreading 
depolarization elicited in the same mouse strain and under the same anesthetic (compare also with Figure 1.1).94 
Note, rrCBF flow curves were averaged by denoting the time just prior to the initial CBF decline after TBI as “zero” 
minutes.  
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To gain further insight into the CBF dynamics after trauma, non-invasive cortical 
light transmission was used to map the temporospatial evolution of CBF changes, which 
cannot be achieved with standard LDF due to its low spatial resolution. These 
experiments revealed the occurrence of a spreading concentric wave of cortical 
hypoperfusion that coincided with the CBF dynamics as assessed by LDF (Figure 2.9). 
Conversely, mice without a spreading wave of cortical hypoperfusion after TBI had no 
significant perturbation of CBF as assessed by LDF. 
 
Figure 2.9 Spatiotemporal evolution of post-traumatic cortical hypoperfusion. (A) Representative view of the 
intact mouse skull after TBI. (B-H) Corresponding time-lapse subtraction images of transilluminated cortical light 
transmission (intensities inverted) show a spreading concentric wave of an initial increase in light transmittance (i.e., 
reduction in cortical CBF; arrows) followed by a central decrease in light transmittance (**) consistent with cortical 
spreading depolarization related CBF dynamics. *indicates the edge of skull at which point the spreading wave 
moves ventrally out of the field of view. Of note, in this mouse the impact center was located ~3 mm cephalad to the 
usually used impact location.  
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Discussion 
Although the complex molecular and cellular mechanisms responsible for post-
traumatic functional deficits are incompletely understood, there is substantial data 
indicating that trauma-induced cerebral hypoperfusion underlyies a significant 
proportion of TBI-related disability.56-64 Yet, the mechanisms driving traumatic cerebral 
hypoperfusion, particularly after mild TBI, remain relatively understudied.223 Several 
different mechanisms may contribute to CBF depression and associated functional 
impairment, including impaired cerebral autoregulation, cerebrovascular reactivity, and 
neurovascular uncoupling.57,62,66,74,77,79-81,83,85-89  
In this study, I demonstrate profound, transient cerebral hypoperfusion after mild 
closed head injury as assessed by non-invasive LDF. Consistent with prior studies, I 
show that worse cerebral hypoperfusion is associated with greater tissue injury and 
worse functional outcome. Importantly, no significant change in the systemic blood 
pressure was observed after injury. Furthermore, lasting cerebral hypoperfusion was 
exclusively noted in the ipsilesional (traumatized) hemisphere, but not in the 
contralesional (non-traumatized) hemisphere. This rules out significant cardio-
respiratory depression as a cause for the CBF alterations as it would have been 
expected to result in a concomitant blood pressure decline, as well as to affect the 
entire brain rather than one hemisphere.  
Although not specifically assessed, these results further argue against a 
significant contribution of cerebral dysautoregulation to the observed histological 
damage and functional impairment. In the setting of impaired autoregulation the CBF 
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follows the systemic blood pressure and, falling below a critical threshold, leads to 
cerebral ischemia and brain injury. However, because the blood pressure remained 
stable within the physiological range, cerebral hypoperfusion as a result of impaired 
autoregulation (even if present) would not be expected to ensue.  
A likely explanation for the noted CBF-responses is the occurrence of CSDs. The 
herein described temporal and spatial CBF dynamics are highly consistent with the 
published prototypical CBF responses to CSD.94 Although CSDs were originally defined 
based on associated electrophysiological phenomena, assessment of the characteristic 
spatial and temporal CBF dynamics in response to a CSD are increasingly utilized as 
accepted surrogate markers for CSDs and to assess related pathophysiology.97,224-226 In 
this respect, the presented data may serve as a valid marker for CSD in the used 
mouse model. Nevertheless, future studies seeking to provide comprehensive insight 
into the association between traumatic CSDs may benefit from additional assessment of 
neuronal electrical activity, which represents the foundation of cerebral function.  
The minimal volume of brain tissue that needs to be simultaneously depolarized 
in the rodent brain to elicit a CSD has been estimated to be ~1mm3 in vivo.227 In the 
herein used TBI model the impacted cortical brain surface is approximately 3 mm2. 
Using the most conservative estimates that only the cortex beneath the impact zone is 
impacted (which is unlikely due to impact-related skull deformation and strain related 
energy propagation to cortical tissues beyond the actual impact zone228,229) and a 
cortical thickness of 1 mm,218,230 a cortical volume of approximately 2 mm3 is directly 
impacted in the used model—well above the critical threshold of 1mm3. Nevertheless, it 
is interesting to note that only a subset of traumatized mice exhibited CSD-like CBF 
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changes (~53%; compare Figure 2.5). However, inter- and intra-individual variability in 
CSD occurrence, propagation, and duration is a well-recognized phenomenon in both 
animal and human studies.95,96,226,231-233 The reasons for this are not well understood, 
but may include differences in the cortical vascular anatomy as well as possible 
cytoarchitectural differences.226 In addition, preceding depolarization, anesthetic depth, 
differences in physiological parameters, baseline CBF, studied species and strain, as 
well as the cortical location have been shown to modulate CSDs.94,224,226 Yet, a 
confounding effect of these factors appear less likely given absent cardiovascular 
depression, occurrence of only a single CSD, non-invasive surgical approach 
(assuaging concerns regarding inadvertent CSD-triggering during animal surgery), and 
identical experimental conditions between studied animals.  
The importance of understanding the association between CSDs and TBI is 
highlighted by the fact that CSDs have been shown to aggravate tissue injury in the 
setting of acute brain injury including after TBI.97-103,234 During a CSD, neurons are 
unable to elicit action potentials because the sustained depolarization remains above 
the threshold for inactivation of the membrane channels that generate action 
potentials.235 In addition to massive ion shifts during a CSD there is an additional 
massive release of amino acid neurotransmitters including glutamate and aspartate.95 It 
has been proposed that CSDs represent a rudimentary form of cell-to-cell signaling; yet, 
a physiological role is unlikely because they do not originate spontaneously in the 
healthy brain.96,236 The release of depolarizing glutamate via N-methyl-D-aspartate 
(NMDA) receptors in conjunction with K+-release into the extracellular space overloads 
the extracellular K+-clearing mechanisms and thus generates depolarization in 
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neighboring regions that gives rise to a self-propagating depolarization wave 
front.94,237,238 Consistent with this hypothesis, tissue susceptibility to CSDs is increased 
in the setting of chemical or genetic astroglial dysfunction as astroglia have a high K+-
buffering capacity.239-241 In addition, it is possible that CSDs propagate directly via gap-
junctional neuron-to-neuron transcellular channels.96 CSDs typically expand at a speed 
of 2-5 mm/min over the cerebral cortex and are characterized by near-complete and 
sustained depolarization of neurons as well as astrocytes causing suppression of 
synaptic activity (hence the original term spreading depression).95,96,99,101,102,242-245 
Because of the substantial metabolic demands to restore homeostasis after a CSD it is 
not surprising that in the injured brain CSDs are associated with deleterious 
consequences on tissue viability by aggravating the already tenuous metabolic supply 
and demand mismatch in the injured brain tissue.97-99 
In summary, my data closes an important knowledge gap by showing that CSD-
related CBF changes are common after mouse TBI. This is an important finding 
because it (i) provides a pathophysiological rationale for the observed CBF responses, 
(ii) helps explain possible inter-animal variability with respect to their histological and 
functional outcome, (iii) and may inform experimental study design. The CSD-related 
CBF alterations have the potential to confound results despite their transient nature and 
may be easily missed unless CBF is continuously assessed after TBI. This observation 
may provide the impetus for human studies to determine whether CSDs occur after mild 
(concussive) head injury, which could provide novel avenues for outcome prediction and 
therapeutic intervention. 
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CHAPTER III: 
ATTENUATED TRAUMATIC AXONAL INJURY AND 
IMPROVED FUNCTIONAL OUTCOME AFTER TRAUMATIC 
BRAIN INJURY IN MICE LACKING SARM1 
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Summary 
Axonal degeneration is a critical, early event in many acute and chronic 
neurological disorders. It has been consistently observed after TBI, but whether axon 
degeneration is a driver of TBI remains unclear, molecular pathways underlying the 
pathology of TBI have not been defined, and there is no efficacious treatment for TBI. 
This study shows that mice lacking the mouse Toll receptor adaptor Sarm1 gene, a key 
mediator of Wallerian degeneration, demonstrate multiple improved TBI-associated 
phenotypes after injury in a closed-head mild TBI model. Sarm1-/- mice developed fewer 
βAPP aggregates in axons of the corpus callosum after TBI as compared to Sarm1+/+ 
mice. Furthermore, mice lacking Sarm1 had reduced plasma concentrations of the 
phophorylated axonal neurofilament subunit H, indicating that axonal integrity is 
maintained after TBI. Strikingly, whereas wild type mice exibited a number of behavioral 
deficits after TBI a strong, early preservation of neurological function in Sarm1-/- animals 
was observed. Finally, using in vivo proton magnetic resonance spectroscopy, tissue 
signatures were found consistent with substantially preserved neuronal energy 
metabolism in Sarm1-/- mice compared to controls immediately following TBI. These 
results indicate that the Sarm1-mediated prodegenerative pathway promotes 
pathogenesis in TBI and suggest that anti-Sarm1 therapeutics are a viable approach for 
preserving neurological function after TBI. 
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Introduction 
It has long been recognized that wide-spread axonal degeneration accompanies 
TBI of all severities and it is thought to represent a key pathological feature underlying 
the observed functional deficits in affected patients.35,106,107,111 However, whether axon 
degeneration is in fact a driver of pathology and functional loss in TBI has not been 
directly tested, the molecular pathophysiology promoting axon loss in TBI remains 
undefined, and there is no efficacious treatment for TBI.111  
A number of studies suggest that axon degeneration after TBI is similar to that of 
Wallerian degeneration,173,174,246,247 which is the catastrophic fragmentation of the distal 
portion of an axon severed from its cell body.173,179 Recently, novel insight into Wallerian 
degeneration and axonal death has been gained by identifying endogenous genes that 
actively promote axon death. It has previously been shown that Wallerian degeneration 
of transsected nerves can be suppressed weeks in homozygous mutant mice lacking 
the Sarm1 gene.180 This exciting observation provided a direct target for potential 
therapeutic intervention during axon degeneration. It also raised the intriguing possibility 
that Sarm1-mediated axon death pathways play a critical role in many neurological 
conditions associated with axonal degeneration including TBI.179  
To test this hypothesis, I use a mouse model of mild closed head injury to 
determine whether loss of Sarm1 mitigates the histological and behavioral 
pathophysiology of TBI by promoting axonal integrity. Such a model is highly relevant 
clinically given epidemiological studies showing that 80% of TBIs are due to blunt, 
closed head trauma.6 If true this would indicate (i) that traumatic axonal injury is driven 
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by molecular pathways similar to those promoting Wallerian degeneration, (ii) that axon 
degeneration through these pathways is associated with the functional deficits observed 
after TBI, and (iii) that Sarm1-based therapies could represent a viable and novel 
opportunity for TBI treatment.  
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Material and Methods 
Experimental design 
This preclinical study was designed to determine whether Sarm1 knockout in 
mice protects from axonal injury and improves outcome after TBI. βAPP 
immunohistology was performed to determine the spatiotemporal distribution of axonal 
pathology after TBI. Assays of plasma pNFH concentration were assessed by 
electrochemiluminescence assay (ECL) to determine axon cytoskeletal breakdown 
products in peripheral blood as a complementary marker of axonal injury. 
Neurobehavioral deficits were determined from acute to subacute time points utilizing 
the NSS, which has been validated to determine neurological sequelae in closed head 
mouse TBI.191 Cerebral neurochemical profiling was conducted using proton magnetic 
resonance spectroscopy (1H-MRS). In addition, parameters shown to influence post-TBI 
outcome including blood gases and CBF were assessed.58 For each experiment, 
G*Power248,249 was used to calculate sample sizes to achieve a power (1-β) of 0.8 to 
detect a significant between-group difference at a two-sided significance level of 0.05. 
All experiments were conducted in a randomized manner and masked to the mouse 
genotype and experimental group.  
 
Ethical approval 
All procedures were approved by the University of Massachusetts Medical 
School Institutional Animal Care and Use Committee (Protocol #A-2405-12).  
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Mice 
Sarm1+/- males and females on the C57BL6/J (Jackson Laboratories) were bred 
to obtain age-matched, male Sarm1+/+ and Sarm1-/- littermate mice.183 All animals were 
socially housed on 12-h light : 12-h dark lighting with food and water ad libitum. In light 
of prior data indicating lack of protection from Wallerian degeneration in Sarm1+/- 
mice,180 this study focused examinations on Sarm1-/- mice.  
Spontaneously breathing mice (n=120) weighing 25.8±2.5 g (age 8-12 weeks) 
were subjected to closed head injury (n=88) or sham injury (n=32) to assess 
neurological deficits (all animals), βAPP staining (n=86; of note βAPP staining was 
repeated at the 48 h time point in a subset of TBI mice [n=7, each] resulting in n=13 for 
this time point), and plasma pNFH concentrations (n=98). In addition, 32 mice were 
used for laser Doppler blood flow analyses to avoid confounding of behavioral and 
neurochemical profiles given the need for prolonged anesthesia. Further, 14 mice were 
used to determine brain neurochemical profiles in vivo using 1H-MRS and 5 mice for 
axon fiber quantification using Toluidine blue staining and light microscopy.  
We excluded 5 Sarm1+/+ mice (1 had a depressed skull fracture, 1 had traumatic 
diastasis of cranial sutures; 1 with subdural hematoma; 1 perioperative death; 1 animal 
moved at impact) and 9 Sarm1-/- mice (1 with pre-TBI skull deformation; 5 had traumatic 
diastasis of cranial sutures; 2 perioperative deaths; 1 animal moved at impact). An 
additional 4 mice were excluded from the 1H-MRS experiments (see below for details). 
Figure 3.1 summarizes the time line of key experiments.  
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Figure 3.1 Experimental timeline. (LDF=laser Doppler flowmetry; 1H-MRS=proton magnetic resonance 
spectroscopy; βAPP=beta amyloid precursor protein; pNFH=plasma phosphorylated neurofilament heavy chain; 
NSS=neurological severity score). 
 
Closed head TBI, cerebral blood flow measurements, neurologic evaluation, and 
βAPP immunohistochemistry 
For details regarding the closed head TBI model, CBF measurements with LDF, 
details of the immunohistological methods to detect βAPP positive axon profiles, clinical 
seizure assessment, quantification of the time to regain sternal recumbency, and 
assessment of the NSS see Chapter II. In this experiment the NSS was assessed prior 
to TBI as well as at 2 h, 24 h, 48 h, 7 d, 14 d, 21 d, and 28 d postoperatively as 
previously described in detail.191  
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Anesthesia, analgesia, and TBI induction 
Animals were anesthetized with isoflurane (5% for induction, 2% for surgery, 
1.5% for maintenance) in room air. Anesthesia was discontinued immediately prior to 
TBI and sham injury. Body temperature was monitored continuously with a rectal probe 
and maintained at 37.0 ± 0.5 °C. To alleviate pain,  animals received 0.05 mg/kg 
subcutaneous buprenorphine (Patterson Veterinary, Devens, MA, USA) 30 min before 
the end of anesthesia and every 6 h afterwards for 24 h. Additionally, each animal 
received 5 mg/kg subcutaneous carprofen (Patterson Veterinary, Devens, MA, USA) at 
the end of the anesthesia.  
In a subset of animals (n=12), whole blood (100 µL) was obtained after trauma 
surgery from the tail artery to measure blood gases (pH, PaO2, PaCO2, base excess, 
HCO3, SaO2), electrolytes (Na+, K+, ionized Ca2+), glucose, hematocrit, and hemoglobin 
concentration (CG8+ Cartridge; VetScan iStat1; Abaxis, Union City, CA).  
 
Toluidine blue staining, axon fiber quantification, and βAPP 
immunohistochemistry 
Three Sarm1+/+ and 2 Sarm1-/- mice were transcardially perfused with 4% 
formaldehyde in 0.9% saline. Brains were removed and post-fixed in 2.5% 
glutaraldehyde in 0.1 M cacodylate buffer, pH 7.2, and left overnight at 4oC.  The 
samples were then rinsed four times (10 min each time) in 0.1 M cacodylate buffer and 
then post-fixed with 1% Osmium Tetroxide for 1h at room temperature. Samples were 
67 
then washed three times with distilled water for 20 minutes each at room temperature 
and then dehydrated through a graded ethanol series of 20% increments, before two 
changes in 100% ethanol.  Samples were then infiltrated first with two changes of 100% 
Propylene Oxide and then with a 50%/50% propylene oxide / SPI-Pon 812 resin 
mixture. The following day three changes of fresh 100% SPI-Pon 812 resin were done 
before the samples were polymerized at 68oC in flat embedding molds. Finally, 1 µm-
thick sections were obtained from 1 mm blocks cut in the mid-saggital plane and from -
1.5 mm to -3.5 mm from Bregma, placed on glass slides, and stained with Toluidine 
Blue.  
Analysis of the axon density in the Toluidine blue stained images (magnification 
63x; resolution 72 dpi; 8 bit grey scale) was performed using CellProfiler 
(http://www.cellprofiler.org).250 Image series were acquired using an oil immersion 
objective with identical camera settings at constant conditions and were processed 
using the NIS-Elements analysis software (Version 4.2, Nikon).  
In a derivation cohort, all axons within 1 randomly sampled 25x25 µm region of 
interest (ROI) from each Sarm1+/+ mouse were manually counted using Photoshop. For 
derivation, CellProfiler was used to automatically quantify axon profiles by adjusting the 
settings until the results matched the manual counts both quantitatively as well as 
qualitatively. Key module settings were as follows: Object size 3 to 20 pixel. 
Thresholding: adaptive as per Otsu method with two-class thresholding and minimizing 
of the weighted variance as well as automatic smoothing. Threshold correction factors 
were 0.0 for the lower and 1.0 for the upper bound. Clumped objects were distinguished 
based on shape and intensity with automatic smoothing for declumping and calculation 
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of minimally allowed distance between local maxima. For validation, CellProfiler and 
manual counts were compared in three separate randomly selected ROIs, indicating 
98.9% accuracy of the automatically counted axon profiles. Following this procedure, 5 
ROIs for each animal were randomly chosen from 3 adjacent toluidine blue stained 
sections to quantify axon profiles for a total of 15 ROIs per animal.  
 
Plasma phosphorylated neurofilament heavy chain 
Under deep isoflurane anesthesia whole blood (500-800 µL) was collected from 
the right ventricle into Eppendorf tubes containing 6 µL ethylenediaminetetracetic acid 
(EDTA). Samples were immediately centrifuged at 3000-g for 15 minutes at 4°C and the 
layer containing plasma immediately removed and stored in low bind Eppendorf tubes 
at −80°C. Plasma pNFH levels were measured using an  ECL and a Meso Scale 
Discovery (MSD, Gaithersburg, MD) SECTOR 2400 Imager. Briefly, MSD 96-well plates 
were coated overnight with mouse anti-human pNFH antibody (EnCor Biotechnology 
Inc., Gainesville, FL, USA). Plasma was diluted 1:1 with 0.5M urea and 40 µL added per 
well for 90 min incubation at room temperature. After washes, 40 µL of sulfo-tagged 
polyclonal anti-pNFH antibody (EnCor Biotechnology) was added to each well and 
incubated for 60 min. After final washes, 150 µL 2X Read Buffer (MSD) was added to 
each well and ECL measured in the SECTOR 2400 Imager. Samples were run in 
triplicate and each experiment repeated at least twice. 
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MRI 
MRI experiments were performed on a 4.7 T/40 cm horizontal magnet (Oxford, 
UK) equipped with 450 mT/m magnetic field gradients and interfaced with a Biospec 
Bruker console (Bruker, Germany). A 1H radiofrequency coil configuration with 23 mm 
inner diameter was used. Throughout the imaging experiment, mice were anesthetized 
with isoflurane (1.5%) delivered through a nose cone and custom-fitted with a head 
restrainer containing a built-in saddle coil. The body temperature of the animal was 
monitored and maintained at 37 °C with a feedback c ontrolled heating pad. For each 
imaging session, anatomical images were acquired using a multi-slice fast spin-echo 
sequence (RARE) (repetition time [TR]: 2000 ms, echo time [TE]: 12 ms, RARE factor: 
8, matrix size: 256 × 256, FOV: 1.8 cm × 1.8 cm, slice number: 18, slice thickness: 0.7 
mm). The 1H-MRS data acquisition was performed using single voxel Point-REsolved 
Spectroscopy Sequence (PRESS) (TR: 2500 ms, TE: 20 ms, Naverage: 512) with variable 
power and optimized relaxation delays (VAPOR) sequence for water suppression, 
following shimming using the FASTMAP sequence. The voxel (3 mm × 3 mm × 3 mm) 
was placed in the right hemisphere and centered beneath the impact zone of each 
animal using high-resolution anatomical images. PRESS was run with exactly the same 
voxel placement and parameters except for water suppression was off and the Naverage 
was set to 16. Imaging was conducted immediately prior to TBI as well as at 2 h and 48 
h after TBI. The overall imaging time including animal setup and sequence optimization 
was approximately 1.5 h.  
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1H-MRS data analysis 
The proton spectra were fit using LCModel (Version 6.3-0l), which analyzes in 
vivo proton spectrum as a linear combination of model in vitro spectra from individual 
metabolite solutions (including l-alanine [Ala], aspartate [Asp], creatine [Cr], 
phosphocreatine [PCr], GABA [γ-Aminobutyric acid], glucose [Glc], glutamine [Gln], 
glutamate [Glu], glycerophosphocholine [GPC], phosphocholine [PCh], glutathione 
[GSH], inositol [Ino], l-lactate [Lac], n-acetylaspartate [NAA], n-acetylaspartylglutamate 
[NAAG], scyllo-inositol [Scyllo], taurine [Tau], total choline [tCh], total n-acetylaspartate 
[tNAA], total creatine [tCr], glutamate and glutamine [Glx], lipids and 
macromolecules).251,252 LCModel utilizes a built-in (simulated) radial basis set for the 
PRESS sequence we are using and produces absolute fits, metabolite quantifications 
(in institutional units), and percent standard deviation of the estimated concentration of 
each metabolite (Cramér-Rao lower bound [CRLB]) as a measure of the reliability of the 
fit. The spectral inclusion criteria (CRLB) were less than 15% for all metabolites. Values 
are institutional units and expressed as mean±S.D. 
One Sarm1-/- mouse died during the first MRI scan and data from an additional 3 
mice (2 Sarm1+/+ and 1 Sarm1-/- mouse) were excluded because their metabolite 
concentrations were more than 2 standard deviations from the mean for their groups. 
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Statistical analysis 
Unless otherwise stated, continuous variables are reported as mean ± S.E.M. 
and categorical variables are reported as proportions. Normality of data was examined 
using Shapiro-Wilk test. Between-group comparisons for continuous variables were 
made with unpaired t-Test, Mann-Whitney U-test, Kruskal Wallis with post-hoc Dunn’s 
method, two-way repeated measures ANOVA, and two-way ANOVA as appropriate. 
Categorical variables were compared using the χ2-test or Fisher exact test as 
appropriate. Two-sided significance tests were used throughout and a two-sided P<0.05 
was considered statistically significant. All statistical analyses were performed using 
IBM® SPSS® Statistics 22 (IBM®-Armonk, NY). 
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Results 
To determine whether Sarm1 knockout attenuates axon pathology after TBI, a 
closed head mouse trauma model was used. The primary outcome of this study was the 
degree of axonal injury as measured by βAPP immunohistology after TBI. Secondary 
outcomes were neurobehavioral deficits measured throughout the 4-week observation 
period using the NSS,191 pNFH concentration as assessed by ECL assay, and cerebral 
neurochemical profiling using 1H-MRS. In addition, physiological parameters shown to 
influence post-TBI outcome including blood gases and CBF were assessed.58  
 
Sarm1-/- is associated with long-term suppression of traumatic axonal injury 
First, the temporal evolution of axonal pathology was determined by quantifying 
the number of βAPP positive aggregates (a marker for axonal injury) in axon profiles 
within the corpus callosum from 2 hours to 4 weeks after TBI. A remarkable reduction of 
axonal βAPP staining in Sarm1-/-animals was observed when compared to Sarm1+/+ 
mice at 2 h and 48 h after TBI (Figure 3.2 A). Importantly, no increase in βAPP 
aggregation in axons of Sarm1-/- mice was observed between 48 hours and the first 28 
days after TBI. This indicates that Sarm1 loss does not merely delay axonal 
degeneration, but is associated with long lasting axonal preservation. Next the spatial 
distribution of axonal βAPP staining was examined within the corpus callosum at the 
time of maximal axonal injury (48 h). While the distribution of βAPP aggregates across 
the width of the corpus callosum was similar between groups (i.e., maximal injury was 
observed beneath the impact zone), a substantial reduction in axonal βAPP staining in 
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Sarm1-/- versus Sarm1+/+ mice was noted (Figure 3.2 B and D). Importantly, when the 
number of axons within the uninjured corpus callosum of sham operated Sarm1+/+ and 
Sarm1-/- mice was quantified no significant difference was observed between groups in 
the number of axons (Figure 3.2 E and F). Therefore, the reduction in βAPP-positive 
axon profiles in Sarm1-/- mice was not biased by differences in baseline axon density 
within the corpus callosum in germ-line knockout mice. Together these data 
demonstrate that loss of Sarm1 is associated with suppressed axon pathology after TBI 
and long-lasting effects on axonal preservation. 
 
Sarm1-/- is associated with reduced plasma concentrations of the axon injury 
marker pNFH  
TBI-related axon injury results in the release of pNFH into the plasma. In a rat 
model of cortical impact, levels of pNFH increased and peaked in the plasma within 48 
h after injury.152 Time dependent increased levels of plasma pNFH have also been 
correlated to the extent of axonal injury and patient outcomes from mild TBI.253,254 
Therefore plasma pNFH concentrations were quantified in this study as an additional 
marker of axonal injury after TBI in Sarm1-/- animals and controls using an ECL. In this 
study the plasma pNFH concentration peaked in wild type mice within 48 h post injury, 
similar to prior reports.152 However, Sarm1-/- mice exhibited no statistically significant 
increase in pNFH in the plasma post-injury (Figure 3.2 C). As with the studies of βAPP, 
this suppression of pNFH release was sustained, lasting for 28 days after TBI.  
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Figure 3.2 Suppressed axon pathology after TBI in mice lacking Sarm1. (A) Temporal evolution of traumatic 
axonal injury as assessed by βAPP-staining in the corpus callosum (n=6 for all time points except 48 h TBI with n=13, 
each; two-way ANOVA) Overall, there were significant group (P=0.013) and time (P<0.001) effects as well as 
presence of a significant group x time (P=0.011) interaction (#P<0.01 versus Sarm1+/+ Sham; *P<0.05, **P<0.01, 
***P<0.001 for between-group differences). (B) Spatial distribution of βAPP-stained axons within the corpus callosum 
48 h after TBI (two-way RM ANOVA). Overall, there were significant differences in the counts of βAPP-stained axons 
between groups (P=0.008), the left-to-right distribution across the corpus callosum (P<0.001), as well as significant 
group x distribution (P<0.001) interaction (*P<0.05, **P<0.01 for between-group differences). (C) Sarm1+/+ mice had 
significantly earlier and higher peak phosphorylated neurofilament heavy chain (pNFH) concentrations as compared 
to Sarm1-/- mice (two-way ANOVA; n=8-9 per group, n=6 for 28 d Sarm1-/-). There were significant group (P=0.016) 
and time (P<0.001) effects as well as presence of a significant group x time (P<0.001) interaction (***P<0.001 for 
between group difference at 48 h; ###P<0.001 for Sarm1+/+ Sham versus Sarm1+/+ TBI at 48 h). (D) Representative 
βAPP-stained sections from the corpus callosum showing βAPP-positive axons in the field of view corresponding to 
“center right” in panel B at low power (asterisks) and higher power (black arrows) magnification. Bars represent 100 
µm. (E) Representative toluidine blue stained transection of the corpus callosum of uninjured Sarm1+/+ and Sarm1-/- 
mice (bar at high power magnification represents 10 µm). (F) Quantification of callosal axons in the mid-sagittal plane 
indicated no significant difference in the number of axons between Sarm1+/+ and Sarm1-/- mice (Mann-Whitney U 
test). For clarity in the figure only significant results are indicated in panels A-C.  
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Improved functional phenotype in Sarm1-/- mice after TBI  
Given the significant axonal preservation observed in Sarm1-/- mice, this study 
explored the possibility that blockade of Sarm1 signaling might also suppress 
neurological defects associated with TBI. Therefore it was investigated whether loss of 
Sarm1 was associated with improved functional outcome after TBI by subjecting 
animals to the NSS: a battery of behavioral tests specifically developed to assess motor 
and neurobehavioral outcome in mice subjected to closed head TBI.191 The NSS is a 
composite of ratings measuring a combination of overall inquisitiveness, postural 
stability, and motor function. The NSS is highly correlated with the severity of brain 
damage; a score of 10 points represents maximal neurological impairment and 0 is 
normal.191 Remarkably, when compared to controls, Sarm1-/- mice had significantly 
attenuated neurological deficits as early as 2 h after TBI (Figure 3.3 A). When the 
temporal evolution of functional deficits was examined, Sarm1+/+ mice were found to 
recover approximately 1 week after TBI whereas Sarm1-/- animals displayed reduced 
functional performance only 24 h post-TBI (Figure 3.3 A). Analysis of the individual NSS 
components revealed that Sarm1-/- was associated with improved outcomes across key 
functional domains tested by the NSS, including more frequent circle exiting at 48 h 
(P=0.026, not shown) and improved straight walk at 2 h (P=0.044, not shown), but not 
startle response and seeking behavior (P>0.05 for each time point). More importantly, 
Sarm1-/- mice had less focal paresis (Figure 3.3 B) and improved postural instability as 
shown by improved balance beam testing across all beam sizes at 2 h post-TBI (P<0.05 
each; Figure 3.3 C-D summarizes the results for the 5, 7, and 10 mm beams). This is 
notable since postural instability is a commonly observed sequela of closed head TBI, 
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highlighting the potential clinical relevance of the observations with Sarm1-/- animals in 
this study.255 Notably, the recovery time from anesthesia (defined as the time to 
spontaneously right from a supine to prone position after discontinuation of anesthesia) 
was similar between Sarm1+/+ and Sarm1-/- groups subjected to TBI versus sham injury 
(Figure 3.3 F). This observation indicates that anesthetic effects are unlikely to have 
contributed to the observed between-group differences in the NSS. Finally, there was 
no significant difference in the incidence of impact seizures between TBI groups 
(P>0.05) and no sham injured animals exhibited seizure activity (Figure 3.3 G).  
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Figure 3.3 Attenuated TBI-induced behavioral deficits in Sarm1-/- mice. (A) Composite neurological severity 
score (NSS; #P<0.05 versus pre-Trauma; *P<0.05 versus Sarm1+/+ TBI; two-way ANOVA). Overall, there were 
significant group and time effects as well as presence of a significant group x time interaction (P<0.001, each). (B-E) 
Temporal evolution of the deficit prevalence in select individual functional components assessed by the NSS 
(***P<0.001, **P<0.01, *P<0.05 for Sarm1+/+ TBI versus Sarm1-/- TBI mice; χ2-test with post-hoc Bonferroni 
correction; for n per group and time point refer to panel A). (F) Similar time to regain sternal recumbency after 
discontinuation of anesthesia in Sarm1+/+ and Sarm1-/- mice subjected to TBI and sham injury, respectively (ANOVA 
on ranks with post-hoc Dunn’s; n=44 for TBI groups and n=16 for sham injury groups). (G) There was no difference in 
the incidence of impact seizures between Sarm1+/+ and Sarm1-/- TBI mice (χ2-test; n=44 for TBI groups and n=16 for 
sham injury groups). All statistical comparisons were made between all 4 experimental groups including for 
assessment of seizure frequency. For clarity in the figure only significant results are indicated in panels A-E. 
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Attenuated neurometabolic dysfunction after TBI in Sarm1-/- mice 
TBI induces dramatic changes in the brain metabolic state. 1H-MRS provides a 
sensitive technique to quantify subtle alterations in neurochemical profiles after TBI that 
relate to functional outcome in patients.256 To determine whether TBI differentially 
affects the cerebral neurochemical profile in wild type versus Sarm1-/- mice, in vivo 1H-
MRS was conducted in a subset of mice prior to injury, 2 h, and 48 h post-TBI. This 
analysis of cerebral metabolites acquired from a single voxel within the right traumatized 
hemisphere (spectral fits with a Cramér-Rao lower bound [CRLB] of <15%) revealed 
that two metabolic parameters (total choline [tCh], and total n-acetylaspartate [tNAA]) 
were transiently reduced at 2 h post-trauma in Sarm1+/+ mice (Table 3.1; Figure 3.4 A 
and B). These metabolites play important roles in myelination and membrane 
metabolism257 and have been previously shown to transiently decrease after TBI in 
rodents.258,259 For example, NAA, which is the most abundant of these 
metabolites,256,258 is a marker of neuroaxonal integrity and viability; its reduction after 
TBI probably reflects impairment of neuronal metabolism.52,256-260 Strikingly, the cerebral 
metabolic depression observed in Sarm+/+ mice after TBI was abolished in the absence 
of Sarm1.  
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Metabolite Time Sarm1+/+ (n=5) Sarm1-/- (n=5) Between group P-value† 
Creatine Pre 161.7 ± 20.9 161.0 ± 23.6 n.s. 
 2 h 157.9 ± 22.4 159.3 ± 18.0 n.s. 
 48 h 156.3 ± 27.0 155.6 ± 28.5 n.s. 
Glu Pre 282 ± 8.5 282.7 ± 6.1 n.s. 
 2 h 266.8 ± 12.5 289.8 ± 16.3 n.s. 
 48 h 278.4 ± 34.0 288.6 ± 29.4 n.s. 
Gln Pre 113.7 ± 9.9 114.0 ± 7.0 n.s. 
 2 h 138.4 ± 46.9 117.1 ± 9.9 n.s. 
 48 h 132.3 ± 21.0 123.6 ± 2.1 n.s. 
Inositol Pre 122.1 ± 10.9 122.4 ± 7.1 n.s. 
 2 h 119.9 ± 10.0 119.3 ± 19.5 n.s. 
 48 h 128.4 ± 13.9 121.0 ± 16.3 n.s. 
NAA Pre 162.5 ± 6.8 174.2 ± 11.2 n.s. 
 2 h 164.1 ± 6.0 173.9 ± 13.8 n.s. 
 48 h 161.1 ± 27.3 174.0 ± 24.7 n.s. 
Taurine Pre 201.8 ± 12.8 204.1 ± 9.5 n.s. 
 2 h 216.2 ± 11.8 219.8 ± 10.7 n.s. 
 48 h 217.7 ± 21.9 227.9 ± 33.0 n.s. 
tCr (Cr+PCr) Pre 187.0 ± 8.7 197.4 ± 2.7 n.s. 
 2 h 177.4 ± 6.0 195.4 ± 10.0 n.s. 
 48 h 191.9 ± 15.2 191.6 ± 16.1 n.s. 
tCho (GPC+PCho) Pre 64.1 ± 2.0 63.7 ± 5.2 0.901 
 2 h 51.3 ± 3.2 60.2 ± 5.3 0.004 
 48 h 65.3 ± 6.2 62.9 ± 2.5 0.369 
Glx (Glu+Gln) Pre 393.1 ± 12.8 395.0 ± 7.8 n.s. 
 2 h 373.6 ± 20.3 397.7 ± 24.6 n.s. 
 48 h 405.0 ± 12.7 398.1 ± 7.8 n.s. 
tNAA (NAA+NAAG) Pre 195.6 ± 15.4 208.6 ± 4.8 0.137 
 2 h 188.1 ± 10.5 209.8 ± 5.9 0.021 
 48 h 202.2 ± 6.2 209.5 ± 16.7 0.391 
Table 3.1 In vivo neurochemical profile alterations in Sarm1-/- and Sarm1+/+ control mice as assessed by 1H-
MRS. Values are institutional units and expressed as mean±S.D. †P-value comparison of Sarm1+/+ with Sarm1-/- mice 
(two-way RM ANOVA with post-hoc Holm-Šídák test). n.s, indicates not significant; Cr=creatine; Gln=glutamine; 
Glu=glutamate; Glx=glutamate and glutamine; GPC=glycerophosphocholine; NAA=n-acetyl aspartate; NAAG=n-
acetyl aspartatyl glutamate; PCho=phosphocholine; PCr=phosphocreatine; tCho=total choline (GPC+PCho); tCr=total 
creatine (Cr+PCr); tNAA=total n-acetyl aspartate (NAA+NAAG).  
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Figure 3.4 Loss of Sarm1 is associated with suppressed TBI-induced alterations in brain neurochemical 
profiles. 1H-MRS showed a transient reduction in (A) tCho (total choline = glycerophosphocholine [GPC] + 
phosphocholine [PCho]) and (B) tNAA (total n-acetyl aspartate = n-acetyl aspartate [NAA] + n-acetyl aspartatyl 
glutamate [NAAG]) within the right hemisphere of Sarm1+/+ but not Sarm1-/- mice (#P<0.05 for overall group 
difference; *P<0.05, **P<0.01 versus Sarm1-/- at 2 h; two way RM ANOVA with post-hoc Holm-Šídák test). 
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Impact of Sarm1-/- on CBF and blood gases after TBI  
Importantly, the effect of Sarm1 loss on 1H-MRS profile changes was not 
associated with changes in CBF as there was no significant difference in the degree of 
post-TBI cerebral perfusion between Sarm1-/- and Sarm1+/+ mice (Figure 3.5). 
Furthermore, there was no difference in the number of animals that had versus did not 
have a CBF reduction below the median 20-min post-TBI CBF (P=0.653, χ2-test), 
suggesting a similar incidence of post-traumatic CSD. 
 
Figure 3.5 Similar CBF response to TBI in Sarm1 wild type and knockout mice. After TBI, relative regional 
cerebral blood flow (rrCBF) decrease to a similar degree in Sarm1+/+ and Sarm1-/- mice. Values reached a nadir of 
~60% of baseline at 20 min following trauma. Subsequently, rrCBF recovered partially to ~75% of baseline values at 
90 min following impact. Sham injured animals displayed a stable rrCBF through the sampling period. Values are 
slightly shifted on the x-axis for better visibility (*P<0.05 versus baseline; RM ANOVA on ranks with post-hoc 
Dunnett's test). For clarity in the figure only significant results are indicated throughout.  
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Lastly, blood gases, electrolytes, glucose, hematocrit, and hemoglobin 
concentration assessed in a subset of animals at the end of anesthesia indicated values 
within the normal physiological range without significant differences between wild type 
and Sarm1-/- mice (Table 3.2). Therefore the observed differences in neuronal 
metabolism as assessed by 1H-MRS were unlikely to be a result of differences in post-
traumatic cerebral CBF responses, hypoperfusion, or hypoxia.77 
 Sarm1+/+ TBI (n=6) Sarm1-/- TBI (n=6) P-value 
pH 7.45 ± 0.07 7.45 ± 0.04 0.971 
PaCO2 (mmHg) 29.6 ± 4.5 27.0 ± 2.6 0.248 
PaO2 (mmHg) 81.2 ± 6.5 86.2 ± 6.0 0.197 
Base excess (mmol/L) -3.9 ± 2.1 -4.7 ± 2.1 0.530 
HCO3- (mmol/L) 19.8 ± 1.8 18.5 ± 0.8 0.116 
SaO2 (%) 96.5 ± 1.0 97.2 ± 0.8 0.235 
Na+ (mmol/L) 144 ± 2 142 ± 1 0.190 
K+ (mmol/L) 4.8 ± 0.3 4.9 ± 0.2 0.675 
iCa2+ (mmol/L) 1.26 ± 0.04 1.23 ± 0.06 0.429 
Glucose (mg/dL) 290 ± 51 286 ± 63 0.902 
Hematocrit (%PCV) 41.7 ± 3.9 41.3 ± 0.8 0.843 
Hemoglobin (g/dL) 14.2 ± 1.3 14.1 ± 0.3 0.838 
Table 3.2 Physiologic parameters at the end of anesthesia. Post-TBI blood gases, electrolytes, glucose, 
hematocrit, and hemoglobin concentration values were within the normal physiological range without significant 
between-group differences between Sarm1+/+ and Sarm1-/- mice subjected to TBI (P>0.05 each; t-Test). Data are 
mean ± S.D. PCV indicates packed cell volume.  
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Discussion 
Wallerian degeneration represents an active process that involves an 
autonomous self-destruction pathway leading to rapid fragmentation of the distal portion 
of a separated axon after a predictable latent phase of 2-3 days.179 Critically, though 
complete axon transection is irreversible, in vitro studies have shown that axonal 
degeneration in a non-transection model can be prevented by WLDS before a 
commitment point is reached.179,261 This suggests that therapies targeting Wallerian 
degeneration pathways may preserve axons in neurological conditions where axon 
degeneration and transection are not immediate.  
This approach is of particular interest to treat TBI-related axon injury, in which the 
majority of damaged axons undergo secondary disconnection (secondary axotomy) with 
a delay of hours to days after the initial trauma.111 However, while WLDS is axon 
protective in a wide range of neurological conditions, it has not been shown to prevent 
axonal degeneration after TBI.179 Given that no pharmacological treatment is yet 
available for patients with debilitating functional impairment due to traumatic axonal 
injury caused by TBI, identifying the potential contribution of a putative active axonal 
death program in traumatic axonal degeneration is important as it holds great promise 
for the identification of original treatment targets and the development of viable 
therapeutic approaches. 
This study shows that loss of Sarm1, the first endogenous gene whose loss 
potently suppresses Wallerian degeneration,180 remarkably attenuates surrogate 
markers of traumatic axonal degeneration and functional deficits after TBI. At 48 h, the 
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median count of injured βAPP-positive axons was reduced by 85% in Sarm1-/- mice. 
Similarly, at 48 h the plasma pNFH-concentration, which is released into the 
bloodstream after axonal injury, was blunted by >90% in Sarm1-/- mice. Importantly, 
though the peak pNFH-concentration was delayed in Sarm1-/- mice, values did not 
exceed those from wild type animals indicating that Sarm1 loss prevents axonal 
degradation rather than merely delaying it. Most important, Sarm1-/- mice exhibited 
substantially preserved neurological function after TBI providing the rationale to develop 
anti-Sarm1 therapies as a means to protect from TBI-related sequelae in humans.  
Precisely how Sarm1 activates axonal degeneration is not known. SARM1 
negatively regulates Toll-like receptor–activated transcriptional programs,262 but the 
exact mechanisms by which it exerts its pro-degenerative function are not yet well 
understood. TIR domain-multimerization, mediated by its SAM domain, appears to be 
required for SARM1‘s pro-degenerative function, while the N-terminal ARM domain is 
auto-inhibitory.179,263,264 Purportedly, the key initial step in the activation of SARM1 
relates to injury-induced axoplasmatic Ca2+ elevation, possibly via Ca2+-calmodulin 
kinase.265,266 The concept that SARM1 acts downstream of Ca2+ is interesting because 
traumatic axonal degeneration is initiated by increases in axoplasmatic Ca2+155,160,267 
with subsequent activation of Ca2+-dependent proteases of the calpain family that drive 
cytoskeletal proteolysis and ultimately axonal degeneration.179,268-270 As an innate 
immunity signaling molecule, SARM1 may be activated through molecules that 
participate in post-traumatic inflammatory cell damage signaling. Conversely, Sarm1 
knockdown has been shown to increase the expression levels of the inflammatory 
cytokines interleukin-6 and interferon-β in the mouse brain,184 which have been linked to 
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outcome after rodent TBI.271-273 This may suggest that SARM1 at least in part mediates 
axon degeneration through modulating the cerebral inflammatory response after TBI. 
Lastly, loss of SARM1 has been demonstrated to protect neurons from ischemic 
injury.183 This is of relevance for TBI, which is commonly associated with post-traumatic 
cerebral hypoperfusion that can contribute to brain injury as shown in this study as well 
as by others.77,274 Indeed, we observed significant hypoperfusion following head impact 
in both Sarm1+/+ and Sarm1-/- mice. Yet, associated cerebral metabolic dysfunction as 
assessed by 1H-MRS was significantly attenuated in Sarm1-/- mice. This observation is 
consistent with prior in vitro studies reporting rescued glycolysis in cultured Sarm1-/- 
neurites275 potentially related to maintained levels of its key substrate nicotinamide 
adenine dinucleotide (NAD+).264,275,276 This also provides a possible explanation for the 
observed early functional protection of Sarm1-/- mice in our model.  
Together, these examples indicate that SARM1 may confer axon protection 
through modulating several mutually not exclusive pathophysiological cascades and 
further study is required to identify the precise role of SARM1-signalling in TBI to 
develop efficacious therapeutic approaches to axon protection. From a therapeutic 
standpoint, it will also be key to establish the time window for intervention. For example, 
in light of experience with other acute brain injuries (such as ischemic stroke) there may 
only be a tight therapeutic window of several hours after TBI111 before the axon injury 
cascade has progressed to the point that Wallerian like degeneration cannot be 
rescued. Further, it has been shown that blocking Wallerian degeneration (such as 
through WLDS) may hinder axonal regeneration.277,278 Accordingly, it will be important to 
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determine whether loss of Sarm1 impairs axonal regeneration and thereby negatively 
impact functional recovery.  
Though the results presented in this thesis are highly suggestive, they do not 
establish direct evidence that observed improvement in functional outcome in Sarm1-/- 
mice was exclusively the result of axonal protection. Thus, further studies may benefit 
from including functional assays to directly determine the contribution of axonal 
functional integrity to sensorimotor and cognitive deficit severity. A further limitation 
relates to the fact that consistent with the mild model severity the number of βAPP 
stained axons in our model was relatively low. Given the low ratio of injured-to-uninjured 
axons no attempt at quantifying the degree of axon loss over the study period was 
made. Thus, further study is required to confirm whether noted attenuation of βAPP 
staining in Sarm1-/- mice truly translates to long-term survival of cerebral axon after TBI. 
In summary, my findings support the notion that Wallerian degeneration may be 
an underlying pathological feature of TBI and its behavioral consequences. My study 
highlights the translational potential of anti-Sarm1 directed therapies as a valuable and 
novel avenue to clinical treatment of TBI and other impact-based injuries in the nervous 
system, and potentially also in a wide range of human neurological diseases associated 
with axonal injury and degeneration. 
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CHAPTER IV: 
COMPREHENSIVE DISCUSSION 
Rationale for Studies 
TBI constitutes a major public health problem as a leading cause of adult death 
and disability worldwide.3 Despite the devastating impact and prevalence of TBI, 
molecular pathways that drive pathology after TBI remain to be clarified.  
Axonal injury and degeneration represents a pathological hallmark of TBI of all 
severities and constitutes a critical determinant of post-traumatic functional 
impairment.106,107 It is now well established that the vast majority of injured axons do 
not, as originally thought, rupture as a direct consequence of the trauma forces but 
rather degenerate as a result of complex biochemical cascades that lead to the 
catastrophic destruction of the axon cytoskeletal components and axotomy over a 
period of hours to days.111,124,139 Moreover, following axotomy the distal axon portion 
undergoes sudden rapid fragmentation along its full length ~72 h after the original 
axotomy, a process termed Wallerian degeneration.106,111,170-174 Intriguingly, this is an 
active process driven by an endogenous “axonal death” pathway that can be 
suppressed for days to weeks in homozygous mutant mice lacking the Sarm1 gene, 
providing evidence of a programmed axonal death pathway.180  
The central goal of this thesis was to use an animal model of TBI that closely 
mimics the human condition and could be used to determine whether blockage of the 
Sarm1 pathway attenuates axonal injury and degeneration as well as neurological 
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sequelae after TBI. If true, this would provide novel insight into the molecular 
mechanisms underlying TAI by showing for the first time that (i) TAI after TBI is 
governed by a Wallerian degeneration-like process and (ii) that this process is mediated 
by a SARM1-associated “programmed axonal death” pathway representing a unique 
and novel target for TBI therapy.  
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Review of Results 
In this dissertation, I provide experimental evidence that the acute adverse 
effects of head trauma on neuro-axonal morphology, brain metabolism, neural function, 
and on whole animal behavior are related to the pro-degenerative axon death signaling 
cascade mediated by SARM1.  
In Chapter II, I characterize the acute CBF responses to TBI. I demonstrate post-
traumatic profound CBF reductions in the traumatized hemisphere and show that 
despite the transient nature of these CBF alterations, animals with lower CBF values 
have greater histological brain damage and worse functional deficits. I identify that the 
specific temporospatial CBF dynamics are consistent with the occurrence of CSDs. My 
observations are important because they establish that cortical hypoperfusion and CSD 
are common in the acute phase after mild TBI and relate to a worse outcome.  
In Chapter III, I present data that animals lacking SARM1 are similar to wild-type 
mice with respect to their baseline neurological function, number of axons within the 
corpus callosum, incidence of impact seizures, time to awakening from anesthesia after 
TBI, physiological parameters, and post-traumatic CBF responses. However, Sarm1 
knockout mice had significantly fewer βAPP positive axons in the corpus callosum, 
reduced plasma pNFH concentrations, 1H-MRS-defined tissue signatures of preserved 
neuronal energy metabolism, and exhibited a strong, early preservation of neurological 
function. This provides evidence that the Sarm1-mediated prodegenerative pathway 
promotes pathogenesis in TBI.  
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Impact of the Results 
The work presented in this thesis has focused on (i) characterizing the acute 
post-traumatic CBF dynamics and their relationship to histological and functional 
outcome; and (ii) the mechanisms of trauma-induced axon degeneration through the 
study of the axon prodegenerative gene Sarm1. These data have been discussed in the 
previous chapters, but what is their potential impact for treating TBI? 
 
Acute post-traumatic cerebral hypoperfusion and metabolic dysfunction 
Moderate-to-severe TBI is associated with profound CBF impairment and 
metabolic derangements that predict a poor outcome.64,70-75 Although mounting 
evidence indicates lasting perturbation of CBF regulation, as well as metabolic 
dysfunction after mild TBI,52,57,66,77-81,256-260 there are no detailed analyses of the acute 
(within one hour) CBF responses after human mild TBI.58,279-283 This lack of human data 
is largely owing to practical and technical limitations because non-invasive assessment 
requires timely transfer of the patient to a facility with advanced neuroimaging 
capabilities.279-282 Experimental studies do not suffer from this limitation because trauma 
onset is under the investigator’s control. Yet, surprisingly few experimental studies have 
determined the CBF within the first hour after mild TBI and none of these has provided a 
detailed characterization of the hyperacute temporospatial CBF dynamics and their 
specific relation to cerebral metabolic dysfunction and overall outcome.57,60,284-287 The 
information gained from this thesis work may therefore be of significant value to the 
field.  
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First, this study included 1H-MRS investigations, which in prior studies 
demonstrated that certain brain metabolites are altered in the acute phase of TBI and 
may aid in diagnosing concussion related injuries.52,257-259,288-291 In particular, similar to 
this study, transient NAA reductions are consistently identified after TBI, indicating 
impaired neuroaxonal metabolism, integrity, and viability.52,256-260 Data for choline, the 
second most frequently altered metabolite after TBI, have been less consistent. While 
some investigators found post-traumatic increases in choline,291 this and other studies 
reported decreased levels indicating post-traumatic changes in membrane integrity and 
metabolism.257-259,292 Overall, the results in this study are consistent with the majority of 
publications and thus add to the notion that 1H-MRS can be used to detect subtle 
neurochemical alterations after rodent mild TBI, which correlate with the degree of 
functional impairment. Nevertheless, caveats in the interpretation of these results relate 
to the fact that 1H-MRS is based on relatively large tissue volume sampling (27 mm3). 
Further, image acquisition is relatively long. Accordingly, 1H-MRS is not well suited to 
track hyperacute changes with high spatial and temporal resolution in rodents and 
should be considered hypothesis generating only. Nevertheless, 1H-MRS may be of 
great value for investigating human TBI to predict cognitive sequelae and provide novel 
insight into the underlying pathophysiology when combined with other imaging 
modalities.293  
Second, by using non-invasive LDF, I provide indirect evidence for CSDs based 
on the prototypical CBF responses observed in TBI mice. It has long been suspected 
that CSDs may occur after mild TBI;104 yet, evidence for this hypothesis had been 
lacking. Importantly, CSDs have been associated with a poor outcome after severe TBI; 
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however, given the catastrophic TBI types in which CSDs have been studied it is not 
possible to determine with certainty whether CSDs are the cause for the observed poor 
outcomes or whether they represent a mere epiphenomenon.100-105 The herein 
described model enables the study of the contribution of CSDs to outcome after brain 
trauma in the absence of confounding pathologies such as ischemia, edema, 
hemorrhage, and other contusion-related injuries.  
Third, in addition to improving the understanding of the underlying 
pathophysiological processes accompanying mild TBI, these data may also inform 
future study designs seeking to investigate novel neuroprotective treatments. The data 
presented herein indicates that CSD and related CBF phenomena are not a uniform 
response to trauma with only a subset of animals exhibiting profound CBF decreases. 
Although CBF was similar across mice as early as one hour after TBI, the earlier CBF 
responses were correlated with the degree of histological and functional outcome. This 
is of particular interest for neuroprotection studies. To date all preclinically tested 
therapies failed to translate from the lab in TBI.294,295 The reasons for this are manifold 
and have been discussed extensively elsewhere.294 However, even in highly rigorous 
studies conducted by an expert consortium, inter-lab variability has been cited as a 
likely contributing factor: “a certain amount of ‘‘wobble’’ in the models was observed 
given the desire to produce behavioral deficits.”295 Among other molecules, this 
consortium sought to determine potential neuroprotective properties of cyclosporine 
A.296 Intriguingly, none of their experimental protocols included CBF measurements. 
Considering that cyclosporine A has been shown to mitigate CSD-related CBF 
decreases,297 it is thus tempting to speculate that unmeasured phenomena with variable 
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prevalence such as the herein described TBI associated CBF reductions could have 
contributed to model variability and bias. From a clinical investigational standpoint, it 
may be possible to refine existing concussion assessment tools to predict recovery after 
a mild TBI by emphasizing symptoms indicative of a CSD.298-300 It may be envisioned to 
use such information to inform concussion trials and select patients for acute pre-
hospital treatment aimed at mitigating CSD related sequelae.94,301,302  
 
Assessment of axonal injury after mild TBI 
Mild TBI accounts for the vast majority of traumatic brain injuries in the United 
States. However, despite its designation, consequences of these “mild” brain injuries 
are often not benign. For this reason, mild TBI has been referred to as the silent 
epidemic because problems such as impaired memory are often not visible. A major 
challenge in outcome prediction after TBI relates to its heterogeneous presentation. 
Most concussions are uncomplicated and resolve within days to weeks. However, it has 
been estimated that up to 15% of affected patients remain symptomatic more than 1 
year after TBI.303,304 Frequent complaints in the first weeks to months after TBI include 
easy distractibility, slow information processing, as well as impairment of executive 
function and memory.305 Although persistent cognitive deficits have been reported 
beyond the first months after mild TBI, there is insufficient evidence whether a single 
mild TBI is associated with long-term cognitive impairment.305 Interestingly, greater 
deficit persistence has been linked to pre-injury neuropsychiatric disorders and 
subacute symptoms do not consistently differ from those in trauma control groups.306,307 
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Therefore, there is a great interest in developing confirmatory tests that allow for 
predicting persistent cognitive deficits attributable to the original TBI.308  
As discussed in the previous chapter, 1H-MRS and CBF measurements may help 
diagnose post-traumatic derangements of cerebral metabolism and blood flow. 
However, these phenomena do not necessarily correlate with TAI and acute imaging is 
challenging to implement clinically.279-282,293 Because TAI represents a key determinant 
of post-TBI outcome,48,54,309,310 non-invasive tests aimed at specifically quantifying the 
degree of TAI are of particular promise. It has been suggested that neurofilaments may 
serve as sensitive markers for injury severity and recovery in both animals and 
humans.150-152,154,253,254,311-313 This thesis work included such an assay and found that 
mild TBI resulted in significant pNFH elevations in wild-type mice that temporally 
correlated with the degree of TAI as assessed by gold standard immunohistological 
techniques. More important, pNFH increases were blunted in Sarm1 knockout mice 
reflecting the attenuated TAI in the absence of SARM1. This indicates that 
neurofilament based assays may not only be used as a marker for TBI / TAI severity but 
may also serve as a sensitive means to determine the efficacy of therapeutic 
approaches to mitigating TAI. A major advantage over conventional histological 
techniques is the ability to non-invasively and serially monitor the progression of TAI in 
rodents, and by extrapolation, in human therapeutic TBI trials.  
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Sarm1‘s possible role in traumatic axonal degeneration 
In this study I show that loss of the Sarm1 gene relates to attenuated neuro-
axonal injury, brain metabolic and behavioral dysfunction after TBI. In particular, by 
using sensitive immunohistological (βAPP) and serological (pNFH) assays I 
demonstrate that Sarm1 knockout mice have significantly attenuated TAI. These 
findings are consistent with the notion that Wallerian degeneration represents a key 
pathological feature driving axonal degeneration and behavioral impairment after TBI.  
The mechanisms by which Sarm1 promotes Wallerian degeneration remain 
incompletely understood. SARM1 is an intracellular protein that co-localizes with the 
outer mitochondrial membrane, microtubules, and is present at synapse.183,185,314 
Although it contains a C-terminal TIR domain (Figure 4.1) indicating a role in toll-like 
receptor (TLR) signaling, loss of Sarm1 does not impair TLR signaling.181,183,315 SARM1 
promotes neuronal death in response to hypoxia and neurotropic viral infection.183,316 
SARM1 has three major domains that seem critical for its regulation and activity. Its N-
terminal domain, which is comprised of multiple ARMs, possesses auto-inhibitory 
function because its ablation renders SARM1 constitutively active to promote axon 
degeneration.263,266,317 Its tandem SAM domains are likely critical for SARM1 
dimerization / multimerization318 to bring its TIR domains into proximity for downstream 
signaling because forced dimerization of the TIR domains triggers rapid axon 
degeneration (Figure 4.1).181,263,266,317  
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Figure 4.1 Model of SARM1 Auto-inhibition and Activation upon Injury. Top: SARM1 is made up of three 
regions: (1) an auto-inhibitory N terminus (Nterm) comprised of multiple ARMs, (2) tandem SAM domains that 
mediate SARM1-SARM1 binding (SAMx2), and (3) a TIR domain that triggers axon degeneration upon 
multimerization. Bottom: SARM1 multimers are inactive (auto-inhibited) in uninjured axons. Injury leads to SARM1 
activation, perhaps through release of inhibition, exposing TIR domain multimers that transmit a pro-destructive signal 
to unknown effector molecule(s). Used with permission from.181      
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As previously discussed, SARM1 appears to act downstream of Ca2+,265,266 which 
represents an interesting concept given the central role of intra axonal Ca2+ to activate 
proteases that subsequently cleave the cytoskeleton and trigger axonal 
degeneration.155,160,179,267-270 Recent work has indicated that SARM1-signaling relates to 
a local energy deficit in injured axons. Specifically, whereas NAD+ levels declined after 
axotomy in wild-type axons, NAD+ loss was substantially suppressed in Sarm1 null 
axons.264,319 Conversely, TIR dimerization resulted in rapid NAD+ depletion within 
minutes, presumably via cleavage into nicotinamide, that was followed by loss of ATP 
and finally axon destruction.264 TIR domains are not known to have any intrinsic 
catalytic activity for which reason it was thought that a, yet to be discovered, co-factor 
executed NAD+ cleavage.320 However, recent data provided unexpected insight into 
how SARM1 may result in NAD+ depletion by showing that the SARM1-TIR domain 
itself might have intrinsic NADase activity.321  
It has been proposed that NAD+ depletion is the essential function of SARM1264 
because (i) SARM1-independent NAD+ breakdown in Sarm1 null cells triggers axon 
degeneration and (ii) SARM1-induced axon destruction can be blocked by NAD+ 
supplementation as well as increased NAD+ synthesis via expression of the NAD+ 
biosynthetic enzymes nicotinamide phosphoribosyltransferase (NAMPT) and 
nicotinamide mononucleotide adenyltransferase (NMNAT).264 However, how SARM1 
cleaves NAD+ is presently unknown.  
Importantly, NMNAT, and specifically its axonal isoform NMNAT2 (NMNAT1 is 
located in the nucleus and NMNAT3 in the mitochondria), is an endogenous axon 
survival factor that synthesizes NAD+ from nicotinamide mononucleotide (NMN) and 
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ATP (adenosine triphosphate).261,322 In fact, it has been shown that WLDs prevents the 
early depletion of NAD+ in injured axons indicating that loss of NMNAT function is a 
crucial event in the Wallerian degeneration pathway.106 It has been hypothesized that 
loss of NMNAT2 may be key for the activation of SARM1. This is based on observations 
that axonal defects and embryonal lethality in NMNAT2 knockout mice are rescued by 
NMNAT2/SARM1 double knockout.323 In addition, that SARM1 function follows a similar 
temporal profile as NMNAT2-loss after axotomy.264 Lastly, NMNAT expression blocks 
axon degeneration, not by increasing NAD+ synthesis, but rather by blocking SARM1-
dependent NAD+ depletion.324 Under this hypothesis, loss of the NAD+ synthesizing 
NMNAT2, which has a short half-life and requires constant transport to the axon, would 
result in SARM1-activation and NAD+ cleavage and thus in catastrophic axonal NAD+ 
loss due to both reduced production and increased destruction of NAD+.181  
But how does SARM1 activation cause axon loss? It has been shown that 
SARM1-dimerization activates mitogen-activated protein kinase (MAPK) signaling, 
which is required for ATP-depletion after axon injury and represents an essential 
component of axon degeneration.317,325 However, a recent study found that MAPK 
signaling is not necessary for NAD+-depletion and axon degeneration induced by 
activated SARM1. This suggests that the MAPK pathway is a critical early event that 
leads to SARM1 activation, but once SARM1 is active the MAPK pathway is no longer 
essential to promote NAD+ and axon loss.326 The authors proposed that MAPK 
signaling may control the levels of the axon survival factor NMNAT2 and thus the axon’s 
susceptibility to degenerate (Figure 4.2).326  
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Nevertheless, whether this proposed pathway applies to TBI remains to be 
clarified. The mouse model used in this thesis work appears well suited to further 
dissect the specific molecular mechanisms driving traumatic axon degeneration and 
investigate how manipulating specific pathways may translate to functional and 
behavioral outcome after TBI. 
 
Figure 4.2 Simplified linear model of the axonal degeneration program. Mitogen-activated protein kinase 
(MAPK) signaling controls the levels of NMNAT2, which blocks SARM1-activation. Upon axon injury, delivery of the 
labile survival factor, nicotinamide mononucleotide adenyltransferase 2 (NMNAT2) via anterograde transport is 
blocked, levels fall below a critical threshold, thus activating SARM1. Activated SARM1 depletes nicotinamide 
adenine dinucleotide (NAD+), leading to loss of adenosine triphosphate (ATP) inducing a metabolic crisis and axon 
fragmentation (for details see text). Modified from.326  
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Future Directions 
The results presented in this dissertation provide several major avenues for 
future studies to further dissect underlying pathophysiology and test treatment 
strategies of mild TBI and TAI.  
 
Exploration of alternative mechanism of Sarm1 mediated axon degeneration 
TBI has a complex pathophysiology, requiring the interaction of multiple cell 
types.189 Germline Sarm1 knockout mice are viable and do not exhibit obvious 
pathology, and brains of Sarm1 knockout mice appear morphologically intact.183 
However, SARM1 appears to be important for embryonic and early postnatal 
development183,185 and in vitro and in vivo Sarm1 knockdown results in reduced 
dendritic arborization.185 Hence, observed protection from TAI in germline Sarm1 
knockout mice may stem from selection of intrinsically more resistant neurons rather 
than due to inhibition of a specific axon death pathway.  
Furthermore, post-traumatic glial pathology has been shown to contribute to 
axonal death.327 SARM1 has been linked to microglial activation328 and it is possible that 
knockout mice have less axon pathology due to attenuated microglial response, which 
would provide a fascinating link between innate immunity and axonal damage sensing. 
Likewise, oligodendroglial apoptosis may lead to axonal demyelination with subsequent 
axon death; thus it is important to determine whether Sarm1 knockout increases 
oligodendroglial survival. 
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Creating mouse models that provide the opportunity to investigate cell-
autonomous effects of Sarm1 gene disruption in the adult brain would be a significant 
advance in the field. Though expression of green fluorescent protein (GFP)-tagged 
Sarm1 has been exclusively observed in neurons,183 low expression beneath the visible 
threshold for GFP-tagged Sarm1 in non-neuronal cell types is possible and does not 
reliably exclude the possibility that non-neuronal sources of SARM1 may activate axon 
death. Creating mouse lines that allow for spatially and temporally controlled 
(conditional) Sarm1 disruption will allow to test whether cell-type specific Sarm1 deletion 
differentially affects axon degeneration after TBI. Such conditional gene knockout can 
be achieved by leveraging the Cre-loxP technology. Cre-loxP is a conditional gene-
targeting system based on the use of the site-specific recombinase Cre that catalyzes 
recombination between two loxP DNA recognition sites. An essential exon within Sarm1 
(gene of interest) is flanked with two loxP sites (floxed) by homologous recombination in 
embryonic stem cells (loxP sites are not native to the mouse genome). Subsequently, 
transgenic mice expressing Cre are crossed with the strain carrying the floxed target 
gene.  
Spatial control (tissue specificity) is achieved by using mice in which Cre is driven 
by a promotor that is specific to the tissue of interest. Once transcribed, Cre excises the 
intervening DNA including the exon from the chromosome creating a null allele in all 
cells where Cre is active. Temporal control of target gene expression is attained by 
using tamoxifen inducible Cre-systems. This approach can limit unwanted Cre activity 
and potential associated side effects such as ectopic recombination due to transient Cre 
expression during development or toxic effects due to prolonged high levels of Cre 
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activity. To accomplish temporal Cre-expression a fusion protein of Cre and a mutant 
estrogen receptor ligand-binding domain (Cre-ERT) are employed. In the absence of the 
specific ligand, the ERT domain is bound by heat shock proteins that presumably block 
recombinase activity. In vivo induction of recombinase activity is achieved by 
administration of tamoxifen or its active metabolite 4-hydroxy-tamoxifen, which releases 
the heat shock protein from the ERT domain resulting in translocation of Cre to the 
nucleus where it can excise the floxed target gene. Importantly, ERT binds tamoxifen 
with greater affinity than endogenous estrogens, which allows Cre-ERT to remain 
cytoplasmic in animals untreated with tamoxifen (newer, more specific, generations of 
this system have been developed and are denoted by ERT1 and ERT2, respectively). 
Several CreERT mouse strains have been developed and are commercially available to 
target neurons, microglia, astroglia, or oligodendroglia for homogenous cell-type specific 
Cre recombination after tamoxifen (but not vehicle) injection.329-332 
To determine, whether SARM1 cell autonomously drives TAI in the brain in vivo, 
Cre-ERT activity can be induced via intraperitoneal injection of tamoxifen (200 mg/kg) 
once a day for 5 consecutive days in mice ~2 months of age prior to TBI.332 Cre-
mediated excision of the floxed exons within the Sarm1 gene results in the transcription 
of aberrant RNA. This results in nonsense-mediated decay of the Sarm1 RNA due to 
frameshift and the unmasking of a premature stop codon, and thus, absent SARM1 
protein production.333 To validate the recombination properties of the Cre lines and 
tamoxifen treatment regimens it will be important to ascertain Cre expression on a 
cellular level, such as by immunohistochemistry using a monoclonal anti-Cre 
recombinase antibody334 or by crossing mice to a global double-fluorescent Cre reporter 
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line.335 Direct detection of SARM1 on a cellular level can be achieved by using Sarm1 
antibodies.185,336 Furthermore, complementary RT-PCR and Western blot can be 
employed to determine Sarm1- and SARM1-expression in the brain, respectively.183,187 
Finally, βAPP-staining after TBI can be used to determine the cell types in which Sarm1 
disruption leads to axon protection following TBI in the inducible Sarm1 knockout mouse 
lines as well as Cre-control lines337 that have received tamoxifen or vehicle, 
respectively.  
Based on in vitro observations that Sarm1 promotes axonal degeneration in the 
absence of other cell types,180,264,321 I expect that only mice with neuron-specific Sarm1 
disruption would be protected from TBI and show attenuated TAI. This would support 
the hypothesis that SARM1 neuron-autonomously mediates axonal death in the brain 
after TBI. Nevertheless, if other mouse lines also show axon protection, this would 
provide exciting new insight into the contribution of other cell types to SARM1-mediated 
axon degeneration following TBI. Conversely, it is possible that no mouse line shows 
protection following localized Sarm1 disruption. This would hint that germline Sarm1 
knockout contributes to brain protection through a different, yet to be discovered, 
mechanism. Alternatively, it could be that Sarm1 disruption in multiple cell types 
simultaneously is needed for protection, which could be determined by combination of 
different Cre lines. Ubiquitously expressed tamoxifen-inducible Cre lines338 could be 
used to determine whether multiple cell types are involved versus presence of a 
developmental confound.339 This would represent a critical experiment, because future 
therapeutic approaches to target Sarm1 in adulthood may not provide significant post-
traumatic axonal protection if protection requires SARM1 absence during development.  
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Possible disadvantages of the Cre-ERT approach relate to the possibility that 
tamoxifen injection results in high mortality rates, which however, could be mitigated by 
oral administration of tamoxifen. Tamoxifen induced recombination efficiency may also 
decline with advancing age,340 requiring injection at an earlier age of 4-6 weeks.337 
Further, tamoxifen-induced recombination may be mosaic (with a hypomorphic 
phenotype) and recombination sensitivity of the Cre reporter may not correlate with that 
of the floxed target gene. Therefore, immunohistochemistry will be required to provide 
an anatomical resolution of SARM1 expression.184,185 
 
Assessment of brain functional connectivity 
TAI-associated disconnection of cerebral functional domains is considered to 
underlie observed persistent neurological deficits after TBI.48,54,309,310,341 Axon protection 
is a promising target for the treatment of brain trauma to improve functional brain 
connectivity and outcome. In this dissertation I show that loss of SARM1 confers 
profound axonal protection from TBI by using histological and serological markers of 
axon integrity. In addition, I demonstrate that Sarm1 knockout mice have significantly 
fewer functional deficits than wild type littermates. However, direct evidence that 
preserved axon integrity translates to improved functional connectivity remains to be 
established.  
To probe axon function and brain functional connectivity several techniques could 
be employed to determine whether Sarm1 knockout preserves functional connectivity 
after TBI. For example, transcallosal evoked responses allow to directly probe axon 
function.342-344 After craniotomy, stimulation electrodes are inserted into the cortex to a 
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depth of approximately 600-800 µm. For non-invasive recording from the contralateral 
cortex, a silver ball-tip electrode is placed on the intact skull at corresponding 
contralateral coordinates. To record transcallosal evoked responses, current pulses are 
applied. Once a stable response is observed, intensity response curves are recorded 
and several consecutive sweeps, obtained at maximal response, will be averaged. 
Using this technique, several prior investigations demonstrated reductions in compound 
action potential amplitudes evoked in the corpus callosum after rodent TBI both in vitro 
and in vivo, with the degree of amplitude reduction correlating with injury severity.342-344 
Accordingly, I would expect that Sarm1 knockout results in greater preservation of peak 
amplitudes after TBI when compared to wild type mice, and that the degree of amplitude 
reduction correlates with the severity of axonal degeneration.342-344 Absence of such a 
difference could indicate that white matter tracts other than the corpus callosum are 
involved in the behavioral deficits observed in this study. This would inform the design 
of future studies investigating functional white matter tract integrity in this model. 
Alternatively, this may indicate the exiting possibility that SARM1 is implicated in post-
traumatic neuronal dysfunction through action in other neuronal structures such as the 
dendrites or synapse. Potential pitfalls of this technique include the confounding of the 
electrophysiological recordings by differences in anesthetic depth and brain 
temperature. Therefore, head temperature will need to be maintained within the 
physiologic range and the anesthetic regimen kept constant between animals. Lastly, 
because the overall TBI severity is mild in the used model, assessment of the 
compound action potential may not be sensitive enough to depict minor differences 
between genetic strains. However, in this case a more severe model could be tested for 
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proof-of-principle (see also next chapter). A more important potential limitation relates to 
the need for a craniotomy. Because the used mouse model is based on a closed-head 
TBI paradigm it would not be possible to establish baseline recordings or conduct serial 
long-term monitoring. Nevertheless, this issue could be mitigated by using appropriate 
control groups (sham injury and comparison with wild type mice) as well as testing 
subgroups at different time points similar to the experimental design used for the 
histological and pNFH analyses in this study. 
An alternative, non-invasive technique to assess brain connectivity is resting 
state functional magnetic resonance imaging (rsfMRI). This MRI-based technique 
studies the temporal dependency between spatially remote neurophysiological events 
that occur when brain regions communicate during rest. Importantly, regions with a 
higher level of functional connectivity also show a higher level of structural connectivity 
through white matter tracts and decreases in white matter integrity can directly affect 
functional connectivity including after mild TBI.345,346 Based on the same general 
principle as rsfMRI, functional connectivity optical intrinsic signal imaging represents a 
novel way to assess brain function.347 It converts changes in reflected light intensity 
from the brain surface to changes in local hemoglobin concentration to determine 
intrinsic functional connectivity and has been successfully applied to determine 
disruption of brain functional connectivity in mouse models of Alzheimer’s disease and 
acute ischemic stroke.347-349 Similar to the invasive transcallosal evoked responses, 
both rsfMRI and functional connectivity optical imaging are susceptible to confounding 
by anesthesia and changes in animal physiology. Accordingly, careful attention to 
anesthetic depth, body temperature, and cardiorespiratory function is needed. 
107 
Repetitive TBI and chronic traumatic encephalopathy 
First evidence for an adverse compounding effect of multiple traumas stems from 
observations in boxers exhibiting cognitive, behavioral, and motor abnormalities almost 
a century ago.350-352 Originally coined “punch drunk” syndrome the term dementia 
pugilistica was subsequently introduced.352,353 Over the last decades, a concept 
emerged that multiple (mild) brain traumas can lead to a unique clinical and pathological 
picture termed chronic traumatic encephalopathy (CTE).354 Clinically, CTE is 
characterized by delayed neurodegeneration, cognitive decline, and behavioral 
abnormalities long after the recovery from the acute effects of the original TBI.354 On a 
pathological level the disease is associated with the accumulation of the microtubule 
associated protein tau in the form of neurofibrillary inclusions (neurofibrillary tangles, 
neuropil threads, and glial tangles) suggesting that repetitive TAI-related breakdown of 
the cytoskeleton and dissolution of microtubules and neurofilaments may serve as a 
toxic gain of function trigger that leads to continued accumulation of tau and to promote 
neurodegeneration.351,354,355 Given its high clinical relevance, SARM1’s role in repetitive 
TBI will need to be elucidated. I have been able to adapt the mouse model used in this 
dissertation to produce repetitive TBI. The preliminary data gained from these 
exploratory analyses indicates that Sarm1 knockout mice have significantly improved 
survival and a better functional outcome (for additional details see Appendix).  
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APPENDIX 
Modeling repetitive TBI in the mouse 
 
Material and Methods 
Ethical approval 
All procedures were approved by the University of Massachusetts Medical 
School Institutional Animal Care and Use Committee (Protocol #A-2405-15).  
 
Mice, TBI paradigm, anesthesia, and analgesia 
Spontaneously breathing male C57BL6/J mice (Jackson Laboratories) age 8-12 
weeks (n=48) were subjected to 5 mild closed head injuries spaced 24 h apart using the 
same weight-drop paradigm as described in chapter II. To alleviate pain, animals 
received 0.05 mg/kg subcutaneous buprenorphine (Patterson Veterinary, Devens, MA, 
USA) 30 min before the end of anesthesia and every 6 h afterwards until 24 h after the 
last TBI. Additionally, each animal received 5 mg/kg subcutaneous carprofen (Patterson 
Veterinary, Devens, MA, USA) after each TBI.  
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Neurological evaluation 
For neurological evaluation the NSS was assessed prior to the first TBI as well as 
at 2 h, 24 h (immediately prior to the second TBI), 26 h, 48 h (prior to the third TBI), 50 
h, 72 h (prior to the fourth TBI), 74 h, 96 h (prior to the fifth TBI), 98 h, as well as 7 d, 14 
d, 21 d, and 28 d after the initial TBI as described in chapter II. The time to sternal 
recumbency and presence of seizure activity was recorded after each TBI as detailed in 
chapter II. 
 
Statistical analysis 
Unless otherwise stated, continuous variables are reported as mean±SEM. 
Between-group comparisons for continuous variables were made with Mann-Whitney U-
test, two-way repeated measures ANOVA, and two-way ANOVA as appropriate. 
Survival was assessed with the Log-Rank test. Categorical variables were compared 
using the Fisher exact test. A two-sided P<0.05 was considered statistically significant. 
All statistical analyses were performed using SigmaPlot 12.5 (Systat Software, Inc., 
Germany) and IBM® SPSS® Statistics 22 (IBM®-Armonk, NY). 
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Results 
Sarm1 knockout is associated with improved survival after repetitive TBI 
Compared to controls, Sarm1 knockout mice had remarkably improved survival 
by 28 days after repetitive (5x) TBI (52% versus 17.4%; P=0.031; Figure A.1).  
 
Figure A.1 Loss of Sarm1 is associated with attenuated mortality after repetitive TBI. Sarm1-/- mice (n=25) had 
significantly improved survival (P=0.031) as compared to Sarm1+/+ mice (n=23).   
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Loss of Sarm1 relates to improved functional outcome repetitive TBI 
Serial evaluation of the NSS showed increasing neurological deficits with repeat 
TBI in both wild type and Sarm1 knockout mice (Figure A.2). Importantly, neurological 
deficit severity was significantly attenuated in mice lacking Sarm1. Furthermore, Sarm1 
wild type mice were found to recover approximately 10 days after the last TBI (2 weeks 
after the first TBI) whereas Sarm1-/- animals displayed no signficant functional 
impairment only 3 days after the last TBI (7 days after the first TBI; Figure A.2).  
 
Figure A.2 Loss of Sarm1 is associated with attenuated neurological deficits after repetitive TBI. Composite 
neurological severity score in the intention-to-treat analysis (i.e., all neurological severity scores were considered up 
to the animals’ death; #P<0.05 versus pre-Trauma; *P<0.05 versus Sarm1 wild type; two-way RM ANOVA with post 
hoc Dunnett's test). Overall, there were significant group (P<0.01) and time (P<0.001) effects as well as presence of 
a significant group x time interaction (P<0.01). For clarity in the figure only significant results are indicated. 
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Similar to the single TBI experiment (see chapter III), the recovery time from 
anesthesia (defined as the time to spontaneously right from a supine to prone position 
after discontinuation of anesthesia) was similar between Sarm1 wild type and Sarm1 
knockout groups (median [25th-75th percentile] 141 s [90 s - 305 s] versus 163 s [73 s – 
227 s]; P=0.838; data not shown). Likewise, although there was a trend towards fewer 
impact seizures in Sarm1 knockout (29%) versus wild type (55%) mice after the first 
TBI, this did not reach significance (P=0.134; not shown). 
Notably, in contrast to the single TBI experiments (compare also with Figure 3.3), 
there was no significant difference in NSS between wild type and Sarm1 knockout mice 
immediately after the first trauma. In particular, wild type animals appeared to have a 
lower than expected NSS at 2 h (2.1±0.5 [repetitive TBI] versus 3.0±0.4 [single TBI]).  
To better understand this apparent inconsistency, I examined the NSS of 
surviving versus non-surviving mice. Overall, non-surviving animals had a worse NSS 
after the first TBI than survivors (P=0.027, not shown). When further stratified by 
genotype, surviving wild type mice had significantly lower 2 h NSS than non-survivors, 
whereas there was no significant difference in Sarm1 knockout mice (P=0.29; Figure 
A.3, P<0.05). 
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Figure A.3 Association between initial neurological deficit severity and survival to day 28. There was a 
significant difference in the 2 h composite neurological severity score between survivors and non-survivors among 
Sarm1 wild type (P<0.05), but not Sarm1 knockout (P=0.29) mice (two-way ANOVA). Overall, there were significant 
survival effects (P=0.019) but the analysis was underpowered for valid interaction analyses.  
 
To gain additional insight into the association of survival status with neurological 
outcome, I conducted a sensitivity analysis that only included data from mice that 
survived for the entire 28 day observation period (complete-case analysis). Overall, the 
results gained from this analysis were in line with the intention-to-treat analysis. Despite 
initially lower composite NSS of Sarm1 knockout versus wild type mice, neurological 
deficit severity was significantly greater in wild type mice after the 5th TBI up to 72 h 
follow up (Figure A.4). Together, these results add to the notion that absence of SARM1 
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mitigates TBI related neurological deficits. However, because of the limited number of 
included animals in the complete-case analyses, statistical tests were underpowered, 
and results should be considered hypothesis generating only. 
 
Figure A.4 Sensitivity analysis of the neurological deficits in surviving mice. Composite neurological severity 
score in the complete-case analysis (i.e., only surviving animals were included; #P<0.05 versus pre-Trauma; *P<0.05 
versus Sarm1 wild type; two-way RM ANOVA post-hoc Holm-Šidák test). Overall, there were significant time 
(P<0.001) effects as well as presence of a significant group x time interaction (P<0.01).  
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Discussion 
In summary, in this preliminary experiment I introduce a repetitive mild closed 
head TBI model in the mouse. This is an important extension of the single TBI model 
because epidemiologic studies have demonstrated that TBI increases the risk for 
dementia and other chronic neurodegenerative diseases.351,354-357 However, while this 
association has been consistently shown even with a single moderate to severe TBI, 
data regarding such an association with single mild TBI is less convincing.358 This has 
led to the hypothesis that there exists a “dose-response” relationship between TBI and 
the risk for chronic cognitive decline and dementia: the risk increases with both trauma 
severity and the number of injuries.358 Under this concept multiple mild brain traumas 
can cause neurological injury and deficits that extend well beyond the initial impact and 
may manifest as CTE.354,359 However, it is important to note that CTE likely represents a 
disease spectrum and not all patients will develop pathology after multiple brain 
injuries.216,359 My model may help elucidate the complex pathophysiology of repeat head 
trauma.  
Most importantly, my preliminary data indicates that loss of Sarm1 remarkably 
attenuates morbidity and mortality after repetitive TBI. Although further characterization 
of this model, particularly with respect to chronic histological brain pathology, is needed, 
these data provide a strong foundation for future studies designed to determine the role 
of the Sarm1 pathway in repeat head injury and possibly CTE pathophysiology. This is 
an important step forward in the field because CTE, unlike most other 
neurodegenerative diseases, can affect healthy adults as early as in their teenage years 
and because there is presently no treatment available for this devastating disease.216 
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Impact of the brain ventricles on traumatic axonal injury: 
A biomechanical hypothesis 
 
 
 
 
 
 
 
 
 
The following work has been published in the Journal of Neurotrauma article published 
as: 
 
Bouley J, Henninger N. Lateral ventricle attenuates underlying traumatic axonal 
injury after closed head injury in the mouse. J. Neurotrauma 2017. doi: 
10.1089/neu.2017.5005. (epub) 
 
Author contributions: J.B. conducted animal surgery, behavioral testing, and 
genotyping. N.H. designed the study, conducted animal surgery, histology analyses, 
statistical analyses, and wrote the paper.  
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Using model systems it has been suggested that the lateral ventricles could act 
as strain relievers and thereby mitigate TAI in adjacent tissues by absorbing energy; yet 
biological evidence for this hypothesis from in vivo studies has been lacking.360,361 In 
this study, attenuated TAI was noted at 48 hours after TBI within the corpus callosum 
overlying the lateral ventricle of wild-type C57BL/6 mice.  
Figure A.5 summarizes the spatial distribution of βAPP positive axons within the 
corpus callosum and indicates conspicuous TAI attenuation beneath the lateral ventricle 
under the impact center. This observation supports the notion that the lateral ventricle 
may indeed attenuate TAI through its proposed energy absorbing capacity. In extension 
of this data, any larger CSF space within the brain may mitigate TAI in adjacent white 
matter tracts in a similar fashion, which may in part explain attenuated TAI in rats with 
ventriculomegaly.362 Nevertheless, although this previous rat study and the mouse 
model used in this dissertation share several features (both models employ a weight 
drop device to produce a closed head impact with associated head acceleration), there 
are also important differences including the use of different rodent species, presence 
versus absence of ventriculomegaly, use of a protective steel disc, as well as impact 
severity and degree of post-traumatic head acceleration.362 Likewise, both models can 
only mimic certain aspects of the heterogeneous human TBI pathophysiology, which is 
influenced by the injury mechanism and proportion of impact and acceleration–
deceleration type forces evoking TAI. Accordingly, the amount and location of axonal 
injury, and thus the extent by which ventricular size can affect it, will be dependent on 
the actual model utilized / the circumstances of the accident. Therefore, a one-to-one 
extrapolation of the results presented in this thesis work to other models and human TBI 
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may not be possible. Future studies seeking to unravel the complex interaction between 
the cerebral ventricles, specifically in the setting of ventriculomegaly, and TAI should 
include detailed assessment of the brain biomechanics during and after TBI to help 
assess the specific contribution of the biological (e.g., inflammation)360-362 versus 
biomechanical (e.g., energy distribution and transfer) tissue response to trauma.  
 
Figure A.5 Brain ventricular system and traumatic axonal injury. At 48 h after TBI significantly fewer beta 
amyloid precursor protein (βAPP) stained axon profiles were counted in the corpus callosum directly overlying the 
lateral ventricles (blue bars) as compared to immediately adjoining fields of view (FOVs). *indicates P<0.05 versus 
FOV3. There was no significant difference in the βAPP counts between FOVs 1 and 2 compared to FOV center right 
after adjustment (for clarity, additional pairwise comparisons are omitted). Analyses were done using repeated 
measures ANOVA on ranks with post-hoc Student-Newman-Keuls method. Bars indicate mean ± 95% confidence 
interval. For details regarding the experimental methods see chapter III. Figure adapted from219 with permission 
(compare also with Figure 3.2).  
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